Table XXX-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH
XXX-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH
XXX-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH
XXX-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH
XXX-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH
XXX-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH
XXX-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-41-1	CH_3	H	H	H	Bz	H	F	H	OH
XXX-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH
XXX-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-41-8	CH_3	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-42-1	Et	H	H	H	Bz	H	F	H	OH
XXX-42-2	Et	H	H	CH_3	Bz	H	F	H	OH
XXX-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-42-8	Et	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001965

Table XXX-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH
XXX-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH
XXX-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH
XXX-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH
XXX-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXX-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-45-8	Ph	*	H	*	Bz	H	F	H	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 001966

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXX-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXX-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXX-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 001967

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXX-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXX-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXX-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXX-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH
XXX-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH
XXX-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH
XXX-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH
XXX-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH
XXX-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH
XXX-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001968



XXXI

Table XXXI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-1-1	CH_3	H	H	H	CH_3	H	F	F	OH
XXXI-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH
XXXI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-1-8	CH_3	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-2-1	Et	H	H	H	CH_3	H	F	F	OH
XXXI-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH
XXXI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-2-8	Et	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001969

Table XXXI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH
XXXI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH
XXXI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-4-1	^{t}Bu	H	H	H	CH_3	H	F	F	OH
XXXI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	F	OH
XXXI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-4-8	^{t}Bu	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-5-1	Ph	H	H	H	CH_3	H	F	F	OH
XXXI-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-5-8	Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001970

Table XXXI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001971

Table XXXI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH
XXXI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH
XXXI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH
XXXI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH
XXXI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH
XXXI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH
XXXI-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-11-1	CH_3	H	H	H	Et	H	F	F	OH
XXXI-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH
XXXI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-11-8	CH_3	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001972

Table XXXI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-12-1	Et	H	H	H	Et	H	F	F	OH
XXXI-12-2	Et	H	H	CH_3	Et	H	F	F	OH
XXXI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-12-8	Et	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH
XXXI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH
XXXI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH
XXXI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH
XXXI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001973

Table XXXI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-15-1	Ph	H	H	H	Et	H	F	F	OH
XXXI-15-2	Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-15-8	Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXXI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXXI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001974

Table XXXI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXXI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXXI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXXI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH
XXXI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH
XXXI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH
XXXI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH
XXXI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH
XXXI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH
XXXI-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001975

Table XXXI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH
XXXI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH
XXXI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH
XXXI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001976

Table XXXI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH
XXXI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001977

Table XXXI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001978

Table XXXI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH
XXXI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH
XXXI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH
XXXI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH
XXXI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH
XXXI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH
XXXI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH
XXXI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH
XXXI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001979

Table XXXI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH
XXXI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH
XXXI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001980

Table XXXI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001981

Table XXXI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH
XXXI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH
XXXI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH
XXXI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH
XXXI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH
XXXI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH
XXXI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-41-1	CH_3	H	H	H	Bz	H	F	F	OH
XXXI-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH
XXXI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-41-8	CH_3	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001982

Table XXXI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-42-1	Et	H	H	H	Bz	H	F	F	OH
XXXI-42-2	Et	H	H	CH_3	Bz	H	F	F	OH
XXXI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-42-8	Et	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH
XXXI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH
XXXI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH
XXXI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH
XXXI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 001983

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXXI-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXXI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXXI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 001984

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXXI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXXI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH
XXXI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table XXXI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXXI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH
XXXI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH
XXXI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 001985

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH
XXXI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH
XXXI-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



XXXII

Table XXXII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-1-1	CH_3	H	H	H	CH_3	H	H	F	OH
XXXII-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH
XXXII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-1-8	CH_3	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-2-1	Et	H	H	H	CH_3	H	H	F	OH
XXXII-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH
XXXII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 001986

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-2-8	Et	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH
XXXII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH
XXXII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH
XXXII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH
XXXII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001987

Table XXXII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-5-1	Ph	H	H	H	CH_3	H	H	F	OH
XXXII-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-5-8	Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001988

Table XXXII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH
XXXII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH
XXXII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH
XXXII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH
XXXII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH
XXXII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH
XXXII-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001989

Table XXXII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-11-1	CH_3	H	H	H	Et	H	H	F	OH
XXXII-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH
XXXII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-11-8	CH_3	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-12-1	Et	H	H	H	Et	H	H	F	OH
XXXII-12-2	Et	H	H	CH_3	Et	H	H	F	OH
XXXII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-12-8	Et	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH
XXXII-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH
XXXII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001990

Table XXXII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH
XXXII-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH
XXXII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-15-1	Ph	H	H	H	Et	H	H	F	OH
XXXII-15-2	Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-15-8	Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXXII-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001991

Table XXXII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXXII-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXXII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXXII-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001992

Table XXXII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXXII-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH
XXXII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH
XXXII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH
XXXII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH
XXXII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH
XXXII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH
XXXII-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH
XXXII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH
XXXII-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001993

Table XXXII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH
XXXII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH
XXXII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001994

Table XXXII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001995

Table XXXII-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH
XXXII-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH
XXXII-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH
XXXII-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH
XXXII-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH
XXXII-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH
XXXII-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH
XXXII-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001996

Table XXXII-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH
XXXII-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH
XXXII-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH
XXXII-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001997

Table XXXII-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001998

Table XXXII-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH
XXXII-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH
XXXII-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH
XXXII-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH
XXXII-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH
XXXII-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH
XXXII-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 001999

Table XXXII-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-41-1	CH_3	H	H	H	Bz	H	H	F	OH
XXXII-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH
XXXII-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-41-8	CH_3	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-42-1	Et	H	H	H	Bz	H	H	F	OH
XXXII-42-2	Et	H	H	CH_3	Bz	H	H	F	OH
XXXII-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-42-8	Et	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH
XXXII-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH
XXXII-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 002000

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH
XXXII-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH
XXXII-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXXII-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-45-8	Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXXII-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 002001

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXXII-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXXII-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXXII-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH

Gilead Exhibit 2029
PGR2023-00046 - Page 002002

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table XXXII-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y
XXXII-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXXII-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH
XXXII-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH
XXXII-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH
XXXII-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH
XXXII-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH
XXXII-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

DOSAGE, ADMINISTRATION, AND USE

A sixth embodiment of the present invention is directed to a composition for the treatment of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, that is intended to include its salts (acid or basic addition salts), hydrates, solvates, and crystalline forms can be obtained, represented by formula **I**.

It is contemplated that the formulation of the sixth embodiment can contain any of the compounds contemplated in any of the aspects of the first, second, third, fourth, and fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention.

The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, hard and soft gelatin capsules, solutions, emulsions, syrups, or

Gilead Exhibit 2029
PGR2023-00046 - Page 002003

suspensions. Compounds of the present invention are efficacious when administered by suppository administration, among other routes of administration. The most convenient manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the severity of the disease and the patient's response to the antiviral medication.

A compound or compounds of the present invention, as well as their pharmaceutically acceptable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as suspensions, emulsions, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the desired dose and pharmacokinetic parameters.

The term "excipient" as used herein refers to a compound that is used to prepare a pharmaceutical composition, and is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

A "pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were

Gilead Exhibit 2029
PGR2023-00046 - Page 002004

absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase "pharmaceutically acceptable salt" of a compound as used herein means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as glycolic acid, pyruvic acid, lactic acid, malonic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, salicylic acid, muconic acid, and the like or (2) basic addition salts formed with the conjugate bases of any of the inorganic acids listed above, wherein the conjugate bases comprise a cationic component selected from among Na^+, K^+, Mg^{2+}, Ca^{2+}, and $NH_gR'''_{4-g}{}^+$, in which R''' is a C_{1-3} alkyl and g is a number selected from among 0, 1, 2, 3, or 4. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt.

Solid form preparations include powders, tablets, pills, capsules, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants,

Gilead Exhibit 2029
PGR2023-00046 - Page 002005

thickeners, solubilizing agents, and the like.

Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs and aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Suitable formulations along with pharmaceutical carriers, diluents and expcipients are described in *Remington: The Science and Practice of Pharmacy* **1995,** edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania, which is hereby incorporated by reference. The compounds of the present invention can also be encapsulated in liposomes, such as those disclosed in U.S. Patent Nos. 6,180,134, 5,192,549, 5,376,380, 6,060,080, 6,132,763, each of which is incorporated by reference. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (e.g., salt formulation), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

A seventh embodiment of the present invention is directed to a use of the compound represented by formula **I** in the manufacture of a medicament for the treatment of any condition the result of an infection by any one of the following viral agents: hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus.

The term "medicament" means a substance used in a method of treatment and/or prophylaxis of a subject in need thereof, wherein the substance includes, but is not limited to, a composition, a formulation, a dosage form, and the like, comprising the compound of formula **I**. It is contemplated that the compound of the use of the compound represented by formula **I** in the manufacture of a medicament for the treatment of any of the antiviral conditions disclosed herein of the seventh embodiment can be any of the compounds contemplated in any of the aspects of the first, second, third, fourth, fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention. A medicament includes, but is not limited to, any one of the compositions contemplated by the sixth embodiment of the present invention.

A eighth embodiment of the present invention is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective amount of the compound represented by formula I to the subject.

A first aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective of at least two or more different compounds falling within the scope of the compound represented by formula I to the subject.

Gilead Exhibit 2029
PGR2023-00046 - Page 002007

A second aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of at least two compounds falling within the scope of the compound represented by formula I to the subject.

It is intended that a subject in need thereof is one that has any condition the result of an infection by any of the viral agents disclosed herein, which includes, but is not limited to, hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus, flaviviridae viruses or pestiviruses or hepaciviruses or a viral agent causing symptoms equivalent or comparable to any of the above-listed viruses.

The term "subject" means a mammal, which includes, but is not limited to, cattle, pigs, sheep, chicken, turkey, buffalo, llama, ostrich, dogs, cats, and humans, preferably the subject is a human. It is contemplated that in the method of treating a subject thereof of the sixth embodiment can be any of the compounds contemplated in any of the aspects of the first, second, and third embodiments or those specifically recited in the tables above, either alone or in combination with another compound of the present invention.

The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.1 and about 10 g, including all values in between, such as 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, and 9.5, per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.5 and about 7.5 g per day, more preferred 1.5 and about 6.0 g per day. Generally, treatment is initiated with a large initial "loading dose" to rapidly reduce or eliminate the virus following by a decreasing the dose to a level sufficient to prevent

Gilead Exhibit 2029
PGR2023-00046 - Page 002008

resurgence of the infection. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.

Therapeutic efficacy can be ascertained from tests of liver function including, but not limited to protein levels such as serum proteins (e.g., albumin, clotting factors, alkaline phosphatase, aminotransferases (e.g., alanine transaminase, aspartate transaminase), 5'-nucleosidase, γ-glutaminyltranspeptidase, etc.), synthesis of bilirubin, synthesis of cholesterol, and synthesis of bile acids; a liver metabolic function, including, but not limited to, carbohydrate metabolism, amino acid and ammonia metabolism. Alternatively the therapeutic effectiveness may be monitored by measuring HCV-RNA. The results of these tests will allow the dose to be optimized.

A third aspect of the eighth embodiment, is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering to the subject a therapeutically effective of a compound represented by formula **I** and a therapeutically effective amount of another antiviral agent; wherein the administration is concurrent or alternative. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours. Examples of "another antiviral agents" include, but are not limited to: HCV NS3 protease inhibitors (see WO 2008010921, WO 2008010921, EP 1881001, WO 2007015824, WO 2007014925, WO 2007014926, WO 2007014921, WO 2007014920, WO 2007014922, US 2005267018, WO 2005095403, WO 2005037214, WO 2004094452, US 2003187018, WO 200364456, WO 2005028502, and WO 2003006490); HCV NS5B Inhibitors (see US 2007275947, US20072759300, WO2007095269, WO 2007092000, WO 2007076034, WO 200702602, US 2005-98125, WO 2006093801, US 2006166964, WO 2006065590, WO 2006065335, US 2006040927, US 2006040890, WO 2006020082, WO 2006012078, WO 2005123087, US 2005154056, US 2004229840, WO 2004065367, WO 2004003138, WO 2004002977, WO 2004002944, WO 2004002940, WO 2004000858, WO 2003105770,

Gilead Exhibit 2029
PGR2023-00046 - Page 002009

WO 2003010141, WO 2002057425, WO 2002057287, WO 2005021568, WO 2004041201, US 20060293306, US 20060194749, US 20060241064, US 6784166, WO 2007088148, WO 2007039142, WO 2005103045, WO 2007039145, WO 2004096210, and WO 2003037895); HCV NS4 Inhibitors (see WO 2007070556 and WO 2005067900); HCV NS5a Inhibitors (see US 2006276511, WO 2006120252, WO 2006120251, WO 2006100310, WO 2006035061); Toll-like receptor agonists (seeWO 2007093901); and other inhibitors (see WO 2004035571, WO 2004014852, WO 2004014313, WO 2004009020, WO 2003101993, WO 2000006529).

A fourth aspect of the eighth embodiment, is directed to a method of treatment in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of a compound represented by formula **I** and another antiviral agent to the subject. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

A fifth aspect of the eighth embodiment, is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering to the subject a therapeutically effective of at least one compound represented by formula **I** and a therapeutically effective amount of another antiviral agent; wherein the administration is concurrent or alternative. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

A sixth aspect of the eighth embodiment, is directed to a method of treatment in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of at least one compound represented by formula **I** and another antiviral agent to the subject. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between


including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

It is contemplated that the another antiviral agent includes, but is not limited to interferon -α , interferon-β, pegylated interferon-α, ribavirin, levovirin, viramidine, another nucleoside HCV polymerase inhibitor, a HCV non-nucleoside polymerase inhibitor, a HCV protease inhibitor, a HCV helicase inhibitor or a HCV fusion inhibitor. When the active compound or its derivative or salt are administered in combination with another antiviral agent the activity may be increased over the parent compound. When the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the nucleoside derivatives. "Concurrent administration" as used herein thus includes administration of the agents at the same time or at different times. Administration of two or more agents at the same time can be achieved by a single formulation containing two or more active ingredients or by substantially simultaneous administration of two or more dosage forms with a single active agent.


It will be understood that references herein to treatment extend to prophylaxis as well as to the treatment of existing conditions. Furthermore, the term "treatment" of a HCV infection, as used herein, also includes treatment or prophylaxis of a disease or a condition associated with or mediated by HCV infection, or the clinical symptoms thereof.

PROCESS FOR PREPARATION

An ninth embodiment of the present invention is directed to a process for preparing the compound of formula I, which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



4




5


wherein the substituents R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, X, Y, R^6, and base have their meanings as disclosed in the Detailed Description of the Invention and X' is a leaving group, such as Cl, Br, I, tosylate, mesylate, trifluoroacetate, trifluorosulfonate, pentafluorophenoxide, p-NO_2-phenoxide, or other commonly used leaving groups as disclosed in *Advanced Organic Chemistry* by March, Fourth Edition. Leaving groups and methods that can be used to effect the formation of a phosphoramidate nucleoside conjugate are found in US 20060142238 and WO 2007095269. Preferably, the leaving group is Cl.

This reaction is performed in an anhydrous aprotic solvent such tetrahydrofuran, dioxane, or both tetrahydrofuran and dioxane, or any functional equivalent thereof, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, collidine, pyridine, 2,6-lutidine, 2, 6-^{t}Bu-pyridine, etc. a tertiary amine base, such as triethylamine, diisopropylethylamine, etc., or an alkyl Grignard reagent, such as tBuMgCl, tBuMgBr, MeMgCl, MeMgBr, etc. The phosphorochloridate (3-10 equivalents) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.

A tenth embodiment of the present invention is directed to a product obtained by a process which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

Gilead Exhibit 2029
PGR2023-00046 - Page 002012

wherein the substituents R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, X, Y, R^6, X', and base have their meanings as disclosed in the Detailed Description of the Invention.

This reaction can be performed in an anhydrous aprotic solvent or other suitable solvent, such as tetrahydrofuran, dioxane, or a mixture of tetrahydrofuran and dioxane, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, a tertiary amine base or tButyl Magnesium Chloride. A phosphorochloridate (3-10 equivalents (or suitable "phosphoro-(leaving group)-date")) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.

Compounds and Preparation


Phosphoramidate compounds of the present invention can be prepared by condensation of a nucleoside analog **5** with a suitably substituted phosphochloridate compound **4** (Scheme 1). The nucleoside analog is made by conventional procedures disclosed in any one of U.S. Published Application Nos. 2005/0009737, 2006/0199783, 2006/0122146, and 2007/0197463, each of which is incorporated by reference in its entirety.

Disclosed 1H-NMR values were recorded on a Varian AS-400 instrument. Mass spectral data were obtain using either a Micromass-Quattromicro API or a Waters Acquity.

Gilead Exhibit 2029
PGR2023-00046 - Page 002013

Thus, by way of example only, a suitably substituted phenol can be reacted with phosphorus oxychloride (**1**) to afford an aryloxy phosphorodichloridate **2** (see Example 1) which is subsequently treated with a acid addition salt of an α-amino acid ester in the presence of TEA to afford an aryloxy phosphorochloridate **4**. This arylalkoxy-amino acid phosphoramidate is reacted with the nucleoside analog to provide the product **I** (for procedure see, e.g., C. McGuigan et al. Antiviral Res. 1992 17:311-321; D. Curley et al. Antiviral Res. 1990 14:345-356; McGuigan et al. Antiviral Chem. Chemother 1990 1(2):107-113).

Scheme 1



The preparation of nucleoside phosphoramidates requires reacting an appropriately substituted phosphochloridate with a nucleoside containing a free 5'-hydroxyl moiety. In cases where only one hydroxyl group is present, preparation of the phosphoramidate usually proceeds smoothly when the phosphochloridate is reacted with

Gilead Exhibit 2029
PGR2023-00046 - Page 002014


the desired nucleoside. In cases where the nucleoside contains more than one free hydroxyl group, preparation of the appropriately protected nucleoside might be required. Silyl, acetonide or other alcohol protecting groups known in the art might be warranted for protection of the sugar moiety. For protection of the nucleoside base, protecting a free amino group may require amidine protection strategy.

Condensation of the phosphochloridate can be carried out on the unprotected nucleoside. Since the 5'-OH group of a nucleoside is much less hindered than the 3'-OH group, selective phosphoramidation is possible under carefully controlled conditions. After condensation to form a protected phosphoramidate nucleoside, deprotection to obtain the free phosphoramidate nucleoside can be carried out using standard protocols for nucleic acid chemistry. In many cases, the desired product is readily separated from the starting material using column chromatography on silica gel. The synthetic scheme is summarized in Scheme 1.

A further understanding of the disclosed embodiments will be appreciated by consideration of the following examples, which are only meant to be illustrative, and not limit the disclosed invention.

EXAMPLE 1

General Procedure for Preparation of phosphorodichloridates



1 2


A solution of the appropriate phenol **R¹-OH** (1eq) and triethylamine (1 eq.) in anhydrous ether was added dropwise to a stirred solution of phosphoryl trichloride **1** (1eq) at 0 °C over a period of 3 hours under nitrogen. Then the temperature was warmed to room temperature, and the reaction was stirred overnight. The triethylamine salt was

Gilead Exhibit 2029
PGR2023-00046 - Page 002015

quickly removed with suction filtration and the filtrate concentrated *in vacuo* to dryness to afford **2** as an oil which was used without further purification.

EXAMPLE 2

General Procedure for Preparation of phosphorochloridates




2 **3** **4**

A solution of triethylamine (2eq) in anhydrous dichloromethane was added dropwise to a solution of aryloxy-phosphodichloridate **2** (1 eq) and the appropriate amino ester **3** (1 eq) in anhydrous dichloromethane with vigorous stirring at -78 °C over a period of 30 to 120 minutes. Then the reaction temperature was allowed to warm to room temperature and stirred over night. Solvent was removed. The residue was washed with ethyl ether and filtered, the filtrate was dried over reduced pressure to give **4**.

EXAMPLE 3

General Procedures for nucleoside phosphoramidate derivatives




4 **5** **I**

Gilead Exhibit 2029
PGR2023-00046 - Page 002016

A solution of the appropriate phosphorochloridate **4** (6.5 equivalents) in anhydrous tetrahydrofuran (THF) was added to a mixture of nucleoside **5** (1 equivalent) and N-methylimidazole (8 equivalents) in anhydrous THF with vigorous stirring at room temperature and the reaction mixture was stirred overnight. The solvent was removed *in vacuo* and the crude was purified by column chromatography and/or preparative thin layer chromatography to give **I**.

EXAMPLE 4

Preparation of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine



2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (1.0g, 1 eq) (Clark, J., et al., J. Med. Chem., 2005, 48, 5504-5508) was dissolved in 10 ml of anhydrous pyridine and concentrated to dryness in vacuo. The resulting syrup was dissolved in 20 ml of anhydrous pyridine under nitrogen and cooled to 0°C with stirring. The brown solution was treated with benzoyl chloride (1.63g, 3eq) dropwise over 10 min. The ice bath was removed and stirring continued for 1.5h whereby thin-layer chromatography (TLC) showed no remaining starting material. The mixture was quenched by addition of water

Gilead Exhibit 2029
PGR2023-00046 - Page 002017

(0.5 ml) and concentrated to dryness. The residue was dissolved in 50 mL of dichloromethane (DCM) and washed with saturated $NaHCO_3$ aqueous solution and H_2O. The organic phase was dried over $NaSO_4$ and filtered, concentrated to dryness to give N^4,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (2.0 g, Yield: 91%).


N^4,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (2.0g, 1 eq) was refluxed in 80% aqueous AcOH overnight. After cooling and standing at room temperature (15 ℃), most of the product precipitated and then was filtered through a sintered funnel. White precipitate was washed with water and co-evaporated with toluene to give a white solid. The filtrate was concentrated and co-evaporated with toluene to give additional product which was washed with water to give a white solid. Combining the two batches of white solid gave 1.50g of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (Yield: 91%).

To a solution of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (1.5 g, 1eq) in MeOH (10 mL) was added a solution of saturated ammonia in MeOH (20mL). The reaction mixture was stirred at 0 ℃ for 30 min, and then warmed to room temperature slowly. After the reaction mixture was stirred for another 18 hours, the reaction mixture was evaporated under reduced pressure to give the residue, which was purified by column chromatography to afford pure compound 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (500 mg, Yield: 60 %).

Gilead Exhibit 2029
PGR2023-00046 - Page 002018

EXAMPLE 5


Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate)



Phenyl methoxyalaninyl phosphorochloridate (1 g, 6.5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (50.1 mg, 15.6%). ^{1}H NMR (DMSO-d_6) δ 1.20-1.27 (m, 6H), 3.58 (d, J = 16.0 Hz, 3H), 3.75-3.92 (m, 2H), 4.015-4.379 (m, 2H), 5.54 (t, J = 10.2 Hz, 1H), 5.83-5.91 (m, 1H), 6.00-6.16 (m, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.22 (s, 1H), 7.35 (t, J = 4.4 Hz, 2H), 7.55 (s, 1H), 11.52 (s, 1H); MS, *m/e* 502 $(M+1)^+$.

EXAMPLE 6

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate)




Gilead Exhibit 2029
PGR2023-00046 - Page 002019

Phenyl methoxy-valyl phosphorochloridate (0.6 g, 3.6 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq) and N-methylimidazole (0.44 g, 9 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (60 mg, 20%). ^{1}H NMR (DMSO-d_6) δ 0.74-0.847 (m, 6H), 1.20-1.28 (m, 3H), 1.89-1.92 (m, 1H), 3.50-3.54 (m, 1H), 3.58 (d, J = 10.4Hz, 3H), 3.72-3.95 (m, 1H), 4.03-4.05 (m, 1H), 4.23-4.43 (m, 2H), 5.56 (t, J = 16.0 Hz, 1H), 5.85-5.92 (m, 1H), 6.01-6.07 (m, 1H), 7.16-7.21 (m, 3H), 7.37 (t, J = 8 Hz, 2H), 7.55-7.60 (m, 1H), 11.52 (s, 1H); MS, *m/e* 530 $(M+1)^+$.

EXAMPLE 7

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate)




4-Bromophenyl methoxy-valyl phosphorochloridate (1 g, 3.4 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (0.2 g,1 eq) and N-methylimidazole (0.35 g, 6 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced

Gilead Exhibit 2029
PGR2023-00046 - Page 002020

pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed reduced pressure to give the desired product (120 mg, 26%). ^{1}H NMR (DMSO-d_6) δ 0.72-0.82 (m, 6H), 1.19-1.26 (m, 3H), 1.86-1.92 (m, 1H), 3.48-3.50 (m, 1H), 3.56 (d, J = 12.0 Hz, 3H), 3.72-3.89 (m, 1H), 3.96-4.03 (m, 1H), 4.22-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.85-5.91 (m, 1H), 5.98-6.13 (m, 1H), 7.15 (d, J = 8.0 Hz, 2H), 7.49-7.56 (m, 3H), 11.53 (s, 1H); MS, *m/e* 608 $(M+1)^+$.

EXAMPLE 8

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate)




4-Bromophenyl methoxy-alanyl phosphorochloridate (0.6 g, 5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-*C*-methyluridine (0.15 g,1 eq)and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (40 mg, 12 %); ^{1}H NMR (DMSO-d_6) δ 1.20-1.26 (m, 6H), 3.57 (d, J = 2.8 Hz, 3H), 3.84 (s, 1H), 3.97-4.03 (m, 1H), 4.21-4.25 (m, 1H), 4.33-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.83-5.89 (m, 1H), 5.98-6.19 (m, 1H), 7.16 (t, J = 10.2 Hz, 2H), 7.52-7.57 (m, 3H), 11.52 (s, 1 H); MS, *m/e* 580$(M+1)^+$.

Gilead Exhibit 2029
PGR2023-00046 - Page 002021

EXAMPLE 9


Preparation of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine



2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (500 mg, 1.9 mmol) was stirred with dimethylformamide dimethyl acetal in DMF (10 mL). The resulting mixture was stirred at room temperature overnight. After solvent removal the crude product was used for next step without further purification.

EXAMPLE 10

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-alanyl phosphate)




Phenyl methoxyalaninyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (62 mg, 20.6%). ^{1}H NMR (DMSO-d_6) δ 1.16 (d, J = 23.2 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H), 3.56 (S, 3H), 3.69-3.75 (d, J = 25.6 Hz, 1H), 3.82-3.86 (m, 1H), 3.96-3.98 (m, 1H), 4.21-4.34 (m, 2H), 5.68 (d, J = 7.2

Gilead Exhibit 2029
PGR2023-00046 - Page 002022

Hz, 1H), 5.75-5.77 (m, 1H), 6.07-6.16 (m, 1H), 7.15-7.19 (m, 3H), 7.2 (d, J = 9.2 Hz, 2H), 7.39 (t, J = 7.8 Hz, 2H), 7.48 (d, J = 9.2 Hz, 1H); MS, *m/e* 501(M+1)$^+$.

EXAMPLE 11

Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate)




4-Bromophenyl methoxy-valyl phosphorochloridate (1.0 g, 3.4 eq.) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.2 g,1 eq.) and N-methylimidazole (0.35 g, 6 eq.) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (59 mg, 13%); ^{1}H NMR (DMSO-d_6) δ 0.74-0.83 (m, 6H), 1.12-1.20 (m, 3H), 1.89-1.92 (m, 1H), 3.49-3.51 (m, 1H), 3.55 (s, 3H), 3.59-3.68 (m, 1H), 3.72-.383 (m, 1H), 4.21-4.39 (m, 2H), 5.70-5.72 (m, 1H), 5.76-5.83 (m, 1H), 6.04-6.16 (m, 1H), 7.15 (d, J = 13.0 Hz, 2H), 7.26 (s, 1H), 7.33 (s, 1H), 7.46-7.55 (m, 1H), 7.56 (d, J = 4.4 Hz, 2H) ; MS, *m/e* 607 (M+1)$^+$.

Gilead Exhibit 2029
PGR2023-00046 - Page 002023

EXAMPLE 12

Preparation of 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate)




Phenyl methoxy-valyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.15 g,1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (86 mg, 42.9 %). ^{1}H NMR (DMSO-d_6) δ 0.72-0.80 (m, 6H), 1.09-1.18 (m, 3H), 1.87-1.92 (m, 1H), 3.47-3.51 (m, 1H), 3.58 (s, 3H), 3.71-3.75 (m, 1H), 3.97 (t, J = 11.2 Hz,1H), 4.22-4.37 (m, 2H), 5.70 (d, J = 8.0 Hz,1H), 5.76-5.84 (m, 1H), 6.01-6.15 (m, 1H), 7.13-7.18 (m, 3H), 7.27 (s, 2H), 7.34 (d, J = 4.0 Hz, 2H), 7.46-7.50 (m, 1H); MS, *m/e* 529 $(M+1)^+$.

EXAMPLES

Example numbers **13-54** and **56-66** are prepared using similar procedures described for examples **5-8.** The example number, compound identification, and NMR/MS details are shown below:

Gilead Exhibit 2029
PGR2023-00046 - Page 002024



Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
13	Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.12-1.16 (m, 3H), 1.20-1.28(m,6H), 3.70-3.90 (m, 2H), 4.00-4.08 (m, 3H), 4.18-4.45 (m, 2H), 5.52-5.58 (m, 1H), 5.85-5.98 (m, 1H), 6.00-6.20 (m, 2H), 7.16-7.23 (m, 3H), 7.37-7.40 (m, 2H) , 7.54-7.60 (m, 1H), 11.54 (s.1H) ; MS, m/e 516.1 (M+1)+
14	1-Napth	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.18-1.30 (m, 6H), 3.78-4.10 (m, 3H), 4.38-4.49 (m, 2H), 4.99-5.11 (m, 2H), 5.28-5.40 (m, 1H), 5.85-6.10 (m, 2H), 6.30-6.41 (m, 1H), 7.28-7.32 (m, 5H), 7.41-7.60 (m, 5H), 7.73-7.76(m, 1H), 7.94-8.11(m, 1H), 8.13-8.15(m, 1H), 11.50 (s.1H) ; MS, m/e 628.4 (M+1)+
15	Ph	H	H	H	Me	1H NMR (DMSO-d_6) δ 1.22 (d, J=22.4 Hz, 3H), 3.59(s, 3H), 3.63-3.69 (m, 2H), 3.74-3.8(m, 1H), 4.02(d, J=11.2 Hz, 1H), 4.23-4.28(m, 1H), 4.40-4.43 (m, 1H), 5.57-5.60 (m, 1H), 5.89(d, J=6.8 Hz, 1H), 6.00-6.06(m, 2H), 7.15-7.23 (m, 3H), 7.35-7.39 (m, 2H),7.52(d, J=8 Hz, 1H), 11.52(s, 1H) ; MS, m/e 487.97 (M+1)+
16	2,4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.22-1.28 (m, 6H), 3.57-3.60 (m, 3H), 3.84-3.92 (m, 2H), 4.00-4.04 (m, 1H), 4.31-4.44 (m, 2H), 5.54-5.61 (m, 1H), 5.85-6.10 (m, 2H), 6.32-6.43 (m, 1H), 7.44-7.54 (m, 3H), 7.72-7.75 (m, 1H), 11.54 (s.1H) ; MS, m/e 570.2 (M+1)+
17	1-Napth	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.15-1.27 (m, 6H), 3.51-3.55 (d, 3H), 3.85-3.96 (m, 2H), 4.00-4.10(m, 1H), 4.30-4.46 (m, 2H), 5.31-5.39 (m, 1H), 5.89-6.05 (m, 2H), 6.22-6.34 (m, 1H), 7.44-7.60 (m, 5H), 7.73-7.77 (m, 1H), 7.93-7.96 (m, 1H), 8.12-8.14 (m, 1H),11.50(s.1H) ; MS, m/e 552.1 (M+1)+
18	Ph	*	H	*	Me	1H NMR (DMSO-d_6) δ 1.19 (d, J=22.8 Hz, 3H), 1.69-1.84 (m, 3H), 1.99-2.04 (m, 1H), 3.16-3.21 (m, 2H), 3.58 (s, 3H), 3.68-3.8 (m, 1H), 4.00 (m, 1H), 4.01-4.13 (m, 1H), 4.22-4.25 (m, 1 H), 4.5 (d, J = 11.2 Hz, 1H), 5.54 (d, J = 8.0 Hz, 1H), 5.86 (s, 1H), 5.6 (d, J = 19.6 Hz, 1H), 7.15-7.2 (m, 3H), 7.34 (t, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 1H), 11.38 (s, 1H) ; MS, m/e 527.93(M+1)+
19	Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.80-0.90 (m, 3H), 1.20-1.35 (m, 8H), 1.48-1.55 (m, 2H), 3.78-3.88 (m, 2H), 3.95-4.08 (m, 3H), 4.22-4.45 (m, 2H), 5.55-5.57(t, 1H), 5.85-6.18 (m, 3H), 7.14-7.23 (m, 3H), 7.35-7.40 (m, 2H), 7.51-7.60 (d, 1H), 11.50 (s.1H) ; MS, m/e 544.2 (M+1)+
20	Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.20-1.30 (m, 6H), 3.72-4.05 (m, 3H), 4.23-4.27 (m, 1H), 4.32-4.45 (m, 1H), 5.07-5.10(t, 2H), 5.52-5.56(t, 1H), 5.86-6.10 (m, 2H), 6.13-6.21(m,1H), 7.15-7.21 (m, 3H), 7.29-7.40 (m, 7H), 7.51-7.56 (d, 1H), 11.50 (s.1H) ; MS, m/e 578.2 (M+1)+
21	4-F-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.28-1.34 (m, 6H), 3.65(d, J= 4 Hz, 3H), 3.85-3.96 (m, 2H), 4.06-4.12 (m, 1H), 4.30-4.34 (m,1H), 4.40-4.47 (m, 1H),

Gilead Exhibit 2029
PGR2023-00046 - Page 002025

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						5.62-5.67 (m, 1H), 5.94-6.01(m, 1H), 6.09 (d, J=18.8 Hz, 1H), 6.17-6.26 (m, 1H), 7.27-7.33(m, 4H), 7.62 (d, J = 7.6 Hz, 1H), 11.61 (s, 1H) ; MS, m/e 519.94(M+1)+
22	4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.22-1.28 (m, 6H), 3.58 (d, 2H), 3.70-3.95(m,2H), 3.95-4.08 (m,1H), 4.23-4.45 (m, 2H), 5.55-5.61(t, 1H), 5.85-6.10 (m, 2H), 6.15-6.23(m,1H), 7.20-7.26 (m, 2H), 7.43-7.46 (m, 2H), 7.54-7.57 (d, 1H), 11.50 (s.1H) ; MS, m/e 536.1 (M+1)+
23	3,4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO-d_6) δ 1.13 (m, 6H), 3.49 (s, 3H), 3.61-3.85 (m, 2H), 3.90-3.93 (m, 1H), 4.16-4.22 (m, 1H), 4.27-4.31 (m, 1H), 5.47-5.52 (m, 1H), 5.82 (d, J = 11.6 Hz, 1H), 5.93(d, J = 19.2 Hz, 1H), 6.15-6.25 (m, 1H), 7.13 (t, J = 9.6 Hz, 1H), 7.43 (d, J = 12Hz, 2H), 7.57 (d, J = 6.0 Hz, 1H), 11.43(s, 1H) ; MS, m/e 569.85 (M+1)+
24	Ph	H	H	Me	2-Bu	1H NMR (DMSO-d_6) δ 0.83 (d, J = 6.8 Hz, 6H), 1.20-1.26 (m, 6H), 1.79-1.86 (m, 1H), 3.73-3.90 (m, 4H), 4.01 (t, J = 11.2 Hz, 1H), 4.21-4.28 (m, 1H), 4.33-4.42 (m, 1H), 5.54 (t, J = 7.6 Hz, 1H), 5.85-5.92 (m, 1H), 5.99-6.13 (m, 2H), 7.19 (t, J = 8 Hz, 3H), 7.36 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 11.52 (s, 1H) ; MS, m/e 544.00 (M+1)+
25	Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.13-1.28 (m, 12H), 3.74-3.81 (m, 2H), 3.95-4.08 (m,1H), 4.20-4.45 (m, 2H), 4.83-4.87 (m, 1H), 5.52-5.58 (m, 1H), 5.84-6.15 (m, 3H), 7.17-7.23 (m, 3H), 7.35-7.39 (m, 2H), 7.54-7.57 (m, 1H), 11.50 (s.1H) ; MS, m/e 530.2 (M+1)+
26	4-MeO-Ph	H	H	Me	n-Bu	1HNMR (400MHz, DMSO-d_6): δ =0.78-0.82 (m, 3H), 1.29-1.47 (m, 8H), 1.49-1.54 (m, 2H), 3.66-3.87 (m, 5H), 3.96-4.02 (m, 3H), 4.21-4.39 (m, 2H), 5.57 (t, J= 12.0Hz, 1H), 5.84-6.05 (m, 3H), 6.90 (dd, J1 =8.0Hz, J2=4.0Hz, 2H), 7.09-7.14 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.55 (d, J =8.0Hz, 1H), 11.48-11.62 (s, 1H)
27	4-F-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.12-1.28 (m, 9H), 3.72-3.94(m,2H) ,3.98-4.10 (m,3H), 4.21-4.42(m,2H), 5.55-5.61 (t, 1H), 5.85-6.20 (m, 3H), 7.18-7.25 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 533.90 (M+1)+
28	4-F-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.13-1.30 (m, 12H), 3.74-3.85(m,2H) ,3.98-4.06 (m,1H), 4.23-4.41(m,2H), 4.83-4.87 (m, 1H), 5.55-5.61 (t, 1H), 5.85-6.12 (m, 3H), 7.18-7.24 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 547.91 (M+1)+
29	4-F-Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.10-1.23 (m, 6H), 3.65-3.89(m,3H) ,4.10-4.30 (m,2H), 4.96-5.00(m,2H), 5.46-5.50 (t, 1H), 5.75-5.96 (m, 2H), 6.04-6.12(m,1H), 7.05-7.11 (m,4H), 7.20-7.24 (d, 5H), 7.42-7.45(d,1H), 11.50 (s.1H) ; MS, m/e 595.94 (M+1)+
30	4-MeO-Ph	H	H	Me	i-Pr	1HNMR (400MHz, DMSO-d_6): δ=1.15-1.27 (m, 12H), 3.71-3.89 (m, 5H), 3.98-4.02 (m, 1H), 4.22-4.25 (m, 1H), 4.33-4.39 (m, 1H), 4.84-4.87 (m, 1H), 5.57 (t, J= 12.0Hz, 1H), 5.91-6.03 (m, 3H), 6.90 (d, J= 8.0Hz, 2H), 7.09-7.14 (m, 2H), 7.55 (d, J= 8.0Hz, 1H), 11.51 (s, 1H)
31	2-Cl-Ph	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.23 (m, 6 H), 3.93-4.00 (m, 3 H), 4.27-4.40 (m, 2H), 5.0(t, J= 7.2 Hz, 2 H), 5.53 (m ,1 H), 5.80-6.0(m , 2 H), 6.30(m, 1H), 7.15 (d, J= 2.4 Hz, 1 H), 7.27 (m, 6 H), 7.51 (m, 3 H), 11.5 (s, 1 H) ; MS, m/e 579.87(M+1)+ / 596.78 (M+18)+

Gilead Exhibit 2029
PGR2023-00046 - Page 002026

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
32	2,4-Cl-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ=0.82 (m, 3 H),1.23 (m, 8 H) , 1.47 (m, 2 H), 3.86 (m, 2 H), 3.84 (m, 3 H),4.27-4.43 (m, 2H), 5.5 (m , 1 H), 6.02 (m ,2 H), 6.35(m, 1H), 7.44 (m, 3 H), 7.77 (m, 1 H), 11.5 (s, 1 H) ; MS, m/e 611.87(M+1)+
33	4-Me-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.14-1.27 (m, 12H), 2.17-2.26 (m, 3H), 3.73-3.82 (m, 1H), 3.99-4.02 (m, 1H), 4.23-4.26 (m, 1H), 4.37-4.40 (m, 1H), 4.82-4.88 (m, 1H), 5.52-5.58 (m, 1H), 5.85-6.07 (m, 3H), 7.01-7.20 (m, 4H), 7.55 (d, J = 16Hz, 1H), 11.51 (s, 1H) ; MS, m/e 543.98 (M+1)+; 1108.86 (2M+23)+
34	4-F-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.82-0.89 (m,3H), 1.20-1.31 (m, 8H), 1.48-1.53 (m,2H), 3.77-3.90 (m,2H) ,3.95-4.10 (m,3H), 4.21-4.45(m,2H), 5.56-5.61 (t, 1H), 5.83-6.20 (m, 3H), 7.18-7.25 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 584.1 (M+23)+
35	3,4-diCl-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ1.12-1.31 (m, 9H), 3.77-3.92 (m,2H), 3.95-4.08 (m,3H), 4.21-4.45(m,2H), 5.56-5.62 (t, 1H), 5.80-6.11 (m, 2H), 6.18-6.33(m,1H), 7.18-7.25 (m,1H), 7.49-7.56 (d, 2H), 7.62-7.67(m,1H), 11.50 (s.1H) ; MS, m/e 606.1 (M+23)+
36	2-Cl-Ph	H	H	Me	i-Pr	1HNMR (400MHz, DMSO-d_6): δ =1.12-1.16 (m, 6H), 1.21-1.27 (m, 6H), 3.79-3.85 (m, 2H), 4.00-4.07 (m, 1H), 4.28-4.32 (m, 1H), 4.38-4.43 (m, 1H), 4.83-4.87 (m, 1H), 5.56 (dd, J1=16.0Hz, J2=8.0Hz, 1H), 5.85-6.12 (m, 2H), 6.20-6.33 (m, 1H), 7.19-7.22 (m, 1H), 7.33 (t, J= 16.0Hz, 1H), 7.48-7.55 (m, 3H), 11.55 (s, 1H)
37	4-MeO-Ph	H	H	Me	Bn	1HNMR(400MHz, DMSO-d_6): δ=1.19-1.26 (m, 6H), 3.69-3.70 (s, 3H), 3.87 (m, 2H), 3.99 (m, 1H), 4.20-4.21 (m, 1H), 4.35 (m, 1H), 5.07-5.09 (m, 2H), 5.54 (t, J = 16.0Hz, 1H), 5.85-5.92 (m, 1H), 6.04-6.10 (m, 2H), 6.86 (d, J= 8.0Hz, 2H), 7.09 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.30-7.34 (m, 5H), 7.53 (s, 1H), 11.52 (s, 1H)
38	Ph	H	H	Me	n-Pen	1H NMR (DMSO-d_6) δ 0.79-0.81 (m, 3H), 1.17-1.23 (m, 10H), 3.74-3.81 (m, 2H), 3.94-3.96 (m, 3H), 4.19-4.36 (m, 2H), 5.49-5.54 (m, 1H), 5.87-6.08 (m,3H), 7.14-7.33 (m, 3H), 7.31-7.35 (m, 2H), 7.51 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 557.9 (M+1)+; 1136.88 (2M+23)+
39	4-Cl-Ph	H	H	Me	i-Pr	1H NMR (DMSO-d_6) δ 1.04-1.19 (m, 12H), 3.76-3.80 (m , 2H), 3.98-4.08 (m, 1H), 4.42-4.42 (m, 2H), 4.82-4.85 (m, 1H), 5.55-5.60 (m, 1H), 5.80-6.20 (m,3H),7.20-7.2 5(m, 2H), 7.43 (d, J = 8.8Hz, 1H), 7.54 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 563.88 (M+1)+; 1148.73 (2M+23)+
40	4-Cl-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.85 (t, J = 7.2 Hz, 3H), 1.22-1.33 (m, 8H),1.45-1.53 (m, 2H), 3.80-3.87 (m, 2H), 3.96-4.04 (m, 3H), 4.24-4.27 (m, 1H), 4.35-4.39 (m, 1H), 5.56-5.61 (m, 1H), 5.82-6.11 (m, 2H), 6.15-6.18 (m, 1H), 7.20-7.56 (m, 4H), 7.51-7.57 (m.1H) , 11.54 (s, 1H); MS, m/e577.95(M+1)+
41	4-Cl-Ph	H	H	Me	Et	1H NMR (DMSO-d_6) δ 1.14 (t, J = 7.0Hz, 3H), 1.20-1.28 (m, 6H),3.77-3.88 (m, 2H), 3.99-4.07 (m, 3H), 4.24-4.28 (m, 1H), 4.34-4.43 (m, 1H), 5.56-5.61 (m, 1H), 5.86-6.13 (m, 2H), 6.15-6.24 (m, 1H), 7.20-7.26 (m, 2H), 7.44 (d, J = 7.6Hz, 2H) , 7.55 (d, J = 7.6Hz,

Gilead Exhibit 2029
PGR2023-00046 - Page 002027

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						1H), 11.55 (s, 1H); MS, m/e549.11(M+1)+
42	4-Me-Ph	H	H	Me	n-Bu	1H NMR (DMSO-d_6) δ 0.79-0.83 (m, 3H), 1.17-1.28 (m, 8H), 1.45-1.47 (m, 2H), 2.22 (d, J = 2.8Hz, 1H), 3.70-3.90 (m, 2H), 3.95-3.98 (m, 3H), 4.10-4.40 (m, 2H), 5.51 (t, 1H), 5.80-5.90 (m, 1H), 5.95-6.05 (m, 2H), 7.02-7.06 (m, 2H), 7.51 (t, J = 4.2Hz , 4H), 7.51 (d, 1H), 11.51 (s, 1H) ; MS, m/e 557.99(M+1)+; 1136.84(2M+23)+
43	4-Me-Phe	H	H	Me	Bn	1H NMR (DMSO-d_6) δ 1.16-1.24 (m, 6H), 2.22 (s , 3H), 3.65-4.03 (m,3H), 4.11-4.38 (m, 2H), 5.04-5.05 (m, 2H), 5.48-5.50 (m, 1H), 5.77-5.87 (m,1H),5.90-6.11 (m, 2H), 6.98-7.10 (m, 4H), 7.28-7.32 (m, 5H), 7.50 (t ,1H), 11.48 (s, 1H) ; MS, m/e 592.00 (M+1)+.
44	Ph	H	H	Et	Me	1H NMR (DMSO-d_6) δ 0.70-0.80 (m, 3H), 1.11-1.26 (m, 3H), 1.42-1.61 (m, 2H), 3.50-3.54 (m, 3H), 3.58-3.80 (m, 2H), 3.91-4.02 (m, 1H), 4.12-4.38 (m, 2H), 5.47-5.52 (m,1H),5.90-6.03 (m, 2H), 7.08-7.16 (m, 3H), 7.26-7.35 (m, 2H),7.48 (t,1H),11.45 (s, 1H) ; MS, m/e 515.95 (M+1)+; 1052.82 (2M+23)+
45	Ph	H	H	Me	4-F-Bn	^{1}HNMR (400MHz, DMSO-d_6): δ 1.20-1.26 (m, 6H), 3.80-3.93 (m, 2H), 3.98 (s, 1H), 4.25-4.26 (m, 1H), 4.36-4.37 (m, 1H), 5.07 (s, 2H), 5.52-5.55 (m, 1H), 5.86-5.87(m, 1H), 5.98-6.04 (m, 1H), 6.14-6.17 (m, 1H), 7.15-7.20 (m, 5H), 7.36 (dd, *J* = 20.0, 8.0 Hz, 4H), 7.54 (s, 1H), 11.55 (s, 1H)
46	4-Cl-Ph	H	H	Me	n-Bu	^{1}HNMR (400MHz, DMSO-d_6): δ 1.21-1.28 (m, 6H), 3.71-3.88 (m, 1H), 3.91-3.98 (m, 1H), 4.00-4.01 (m, 1H), 4.23-4.27 (m, 1H), 4.35-4.38 (m, 1H), 5.08 (d, *J* = 4.0Hz, 2H), 5.57 (dd, *J* = 12.0, 8.0 Hz, 1H), 5.91 (d, *J* = 8.0 Hz, 1H), 6.01 (d, *J* = 8.0 Hz, 1H), 6.22-6.24 (m, 1H), 7.17-7.23 (m, 2H), 7.31-7.40 (m, 7H), 7.53 (s, 1H), 11.50 (s, 1H)
47	Ph	H	H	Me	3-Me-1-Bu	^{1}H NMR (DMSO-d_6) δ 0.80-0.82 (m, 6H), 1.18-1.40 (m, 8H), 1.50-1.58 (m, 1H), 3.71-3.82 (m, 3H), 3.97-3.4.01 (m, 3H), 4.21-4.40 (m, 2H), 5.30(t, *J* = 8.6 Hz, 1H), 5.81-6.10 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.48 (d, *J* = 8.4 Hz, 1H), 11.38 (s, 1H) ; MS, *m/e* 557.98 $(M+1)^+$; 1136.88 $(2M+23)^+$
48	3,4-diCl-Ph	H	H	Me	Bn	^{1}H NMR (DMSO-d_6) δ 1.05-1.37 (m, 6H), 3.71-3.82 (m, 1H), 3.87-4.02 (m, 2H), 4.28-4.29 (m, 1H),4.36-4.38 (m, 1H),5.04 (d, *J* = 5.2Hz, 2H), 5.55-5.64 (m, 1H), 5.85-5.94 (m, 1H), 6.00-6.05 (m, 1H), 6.29-6.40 (m, 1H),7.17-7.24 (m, 1H), 7.30-7.41 (m, 5H), 7.45-7.58 (m, 2H), 7.61 (d, *J* = 4.0Hz, 1H), 11.53 (s, 1H); MS, *m/e*545.80$(M+1)^+$;
49	Ph	H	H	Me	c-Hex	^{1}H NMR (DMSO-d_6) δ 1.18-1.41 (m, 12H), 1.59-1.67 (m, 4H), 3.74-13.80 (m, 1H), 3.96-4.02 (m, 1H), 4.19-4.26 (m, 1H), 4.31-4.39 (m, 1H), 4.60 (s, 1H), 5.52 (t, *J* = 7.8 Hz, 1H), 5.80-6.09 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.52 (d, *J* = 8 Hz, 1H), 11.50 (s, 1H) ; MS, *m/e* 569.98 $(M+1)^+$; 592.14 $(M+23)^+$
50	Ph	H	Me	H	n-Bu	1H NMR (DMSO-d_6) δ 0.76 (t, J = 7.2Hz, 3H), 1.10-1.22 (m, 8H), 1.38-1.43 (m, 2H), 3.72-3.75 (m, 2H), 3.87-3.93 (m, 3H), 4.14-4.21 (m, 1H), 4.23-4.33 (m, 1H), 5.46-5.54 (m, 1H), 5.84-6.11 (m, 3H), 7.09-7.14 (m, 2H), 7.27-7.32 (m, 2H), 7.34-7.51 (m, 1H), 11.47 (s, 1H); MS, m/e543.98(M+1)+
51	Ph	H	Me	H	i-Pr	1H NMR (DMSO-d_6) δ 1.39 (d, J = 7.2Hz, 6H), 1.19-1.29 (m, 6H),

Gilead Exhibit 2029
PGR2023-00046 - Page 002028

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						3.65-3.75 (m, 2H), 3.95-4.05 (m, 1H), 4.20-4.22 (m, 1H), 4.31-4.33 (m, 1H), 4.79-4.82 (m, 1H), 5.48-5.57 (m, 1H), 5.84-5.91 (m, 1H), 5.96-6.07 (m, 2H), 7.12-7.35 (m, 5H), 7.44-7.54 (m.1H), 11.49(s, 1H); MS, m/e529.96 (M+1)+
52	Ph	H	Me	H	Bn	^{1}H NMR (DMSO-d_6) δ 1.18-1.28 (m, 6H), 3.70-3.83 (m, 1H), 3.87-3.94 (m, 1H), 3.99-4.01 (m, 1H), 4.23-4.26 (m, 1H), 4.33-4.37 (m, 1H), 5.03-5.12 (m, 2H), 5.51-5.59 (m, 1H), 5.87-5.90 (m, 1H), 5.95-6.07 (m, 1H), 6.10-6.27 (m, 1H), 7.15-7.23 (m, 3H), 7.31-7.38 (m, 7H), 7.47-7.56 (m, 1H), 11.50 (s, 1H); MS, m/e577.99 (M+1)+
53	2-Cl-Ph	H	H	Me	n-Bu	^{1}HNMR (400MHz, DMSO-d_6): δ 0.81-0.86 (m, 3H), 1.21-1.31 (m, 8H), 1.46-1.52 (m, 2H), 3.84-3.90 (m, 2H), 3.97-4.04 (m, 3H), 4.27-4.41 (m, 2H), 5.53-5.58 (m, 1H), 5.82-5.95 (m, 1H), 5.96-6.10 (m, 1H), 6.27-6.31 (m, 1H), 7.19-7.22 (m, 1H), 7.34 (dd, *J* = 8.0, 4.0 Hz, 1H), 7.47-7.55 (m, 3H), 11.55 (s, 1H)
54	4-Br-Ph	H	H	Me	i-Pr	^{1}HNMR (400MHz, DMSO-d_6): δ 1.10-1.14 (m, 6H), 1.20-1.27 (m, 6H), 3.74-3.81 (m, 2H), 3.99-4.01 (m, 1H), 4.21-4.25 (m, 1H), 4.37-4.38 (m, 1H), 4.81-4.85 (m, 1H), 5.58 (dd, *J* = 8.0, 4.0 Hz, 1H), 5.82-5.95 (m, 1H), 5.96-6.09 (m, 1H), 6.10-6.13 (m, 1H), 7.18 (dd, *J* = 12.0, 8.0 Hz, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H)
55	4-F-Ph	H	H	Me	c-Hex	^{1}H NMR (DMSO-d_6) δ 1.20-1.44 (m, 12H), 1.60-1.71 (m, 4H), 3.75-4.02 (m, 2H), 3.94-4.02 (m, 1H), 4.19-4.26 (m, 2H), 4.59-4.61 (m, 1H), 5.57 (t, *J* = 8.4 Hz, 1H), 5.85-6.06 (m, 3H), 7.17-7.23 (m, 4H), 7.54 (d, *J* = 8.4 Hz, 1H), 11.50 (s, 1H) ; MS, *m/e* 587.92 $(M+1)^+$
56	4-Br-Ph	H	H	Me	c-Hex	^{1}HNMR (400MHz, DMSO-d_6): δ =1.18-1.46 (m, 12H), 1.61-1.69 (m, 4H), 3.75-3.82 (m, 2H), 3.95-4.08 (m, 1H), 4.25-4.28 (m, 1H), 4.38 (s, 1H), 4.60-4.62 (m, 1H), 5.56-5.60 (m, 1H), 5.82-5.95 (m, 1H), 6.02-6.20 (m, 2H), 7.09-7.20 (m, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H) MS, *m/e* 650.0 $(M+3)^+$
57	Ph	H	H	Et	i-Pr	^{1}HNMR (400MHz, DMSO-d_6): δ =0.75-0.82 (m, 3H), 1.12-1.26 (m, 9H), 1.52-1.59 (m, 2H), 3.55-3.68 (m, 1H), 3.72-3.85 (m, 1H), 3.95-4.08 (m, 1H), 4.18-4.28 (m, 1H), 4.32-4.41 (m, 1H), 4.83-4.86 (m, 1H), 5.55 (m, *J*= 7.6Hz, 1H), 5.99-6.04 (m, 2H), 6.05-6.10 (m, 1H), 7.14-7.21 (m, 3H), 7.33-7.37 (m, 2H), 7.52-7.54 (m, 1H), 11.53 (s, 1H) ; MS, *m/e*566.07$(M+23)^+$
58	Ph	H	H	Et	c-Hex	^{1}HNMR (400MHz, DMSO-d_6): δ 0.75-0.88 (m, 3H), 1.26-1.46 (m, 9H), 1.52-1.69 (m, 6H), 3.60-3.63 (m, 1H), 3.72-3.90 (m, 1H), 4.02-4.03 (m, 1H), 4.24-4.27 (m, 1H), 4.37-4.38 (m, 1H), 4.63-4.65 (m, 1H), 5.55 (dd, *J* =8.0Hz, 4.4Hz, 1H), 5.80-5.95 (m, 1H), 6.00-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.34-7.38 (m, 2H), 7.54 (d, *J* =8.0Hz, 1H), 11.55 (s, 1H); MS, *m/e* 584.01 $(M+1)^+$, 606.17 $(M+23)^+$
59	4-F-Ph	H	H	Et	c-Hex	^{1}H NMR (DMSO-d_6) δ 0.75-0.84 (m, 3H), 1.24 (d, *J* = 22.8Hz, 3H), 1.29-1.47 (m, 6H), 1.51-1.70 (m, 6H), 3.59-3.66 (m, 1H), 3.77-3.84 (m, 1H), 3.98-4.04 (m, 1H), 4.21-4.27 (m, 1H), 4.34-4.41 (m, 1H), 4.60-4.65 (m, 1H), 5.56-5.60 (m, 1H), 5.84-5.90 (m, 1H), 6.00-6.08

Gilead Exhibit 2029
PGR2023-00046 - Page 002029

Ex.	R^1	R^2	R^{3a}	R^{3b}	R^4	NMR/MS
						(m, 2H), 7.20-7.24 (m, 4H), 7.56(d, *J* = 8.0Hz, 1H), 11.49 (s, 1H); MS, *m/e* 602.00(M+1)$^+$
60	Ph	H	H	Me	F-CH_2-CH_2-	^{1}H NMR (DMSO-d_6) δ 1.18-1.25(m, 6H), 3.71-3.89 (m, 2H), 3.92-3.99 (m, 1H), 4.19-4.27 (m, 4H), 4.48-4.61 (m, 2H) , 3.94-3.98 (m, 2H), 4.11-4.23 (m, 4H), 5.47-5.52 (m, 1H), 6.01-6.11 (m, 1H), 5.90-6.14 (m, 2H), 7.15-7.21 (m, 3H), 7.32-7.36 (m, 2H), 7.46-7.57 (m, 1H), 11.49 (s,1H) ; MS, *m/e* 533.86 (M+1)$^+$
61	Ph	H	H	Me	F_2CH-CH_2-	^{1}H NMR (DMSO-d_6) δ 1.17-1.24 (m, 6H), 3.67-3.81 (m, 1H), 3.89-3.98 (m, 2H),4.21-4.36 (m, 4H), 5.48-5.53 (m, 1H)，5.82-6.05 (m, 2H), 6.18-6.22 (m, 2H), 7.15-7.20 (m, 3H), 7.32-7.36 (m , 2H), 7.51 (s, 1H),11.50 (s, 1H) ; MS, *m/e* 551.92 (M+1)$^+$;
62	Ph	H	H	Me	$(CF_3)_2$-CH-	^{1}H NMR (DMSO-d_6) δ 1.13-1.29 (m, 6H), 3.67-3.81 (m, 1H), 3.94-4.32 (m, 4H), 5.47 (t, *J* = 8 Hz 1H)，5.82-6.01 (m, 2H), 6.33-6.36 (m, 1H), 6.70-6.78 (m, 1H), 7.09-7.15 (m, 3H), 7.28-7.32 (m , 2H), 7.43-7.46 (m, 1H),11.44 (s, 1H) ; MS, *m/e* 637.90 (M+1)$^+$
63	Ph	H	H	Me	$(CH_2F)_2$ -CH-	^{1}H NMR (DMSO-d_6) δ 1.20-1.29 (m, 6H), 3.70-3.90 (m, 1H), 3.91-4.12 (m, 2H), 4.20-4.33 (m, 1H), 4.35-4.48 (m, 1H), 4.52-4.55 (m, 2H)，4.63-4.67 (m, 2H), 5.20-5.35 (m, 1H), 5.56 (t, *J* = 8.4 Hz, 1H), 5.80-5.95 (m, 1H), 5.95-6.10 (m, 1H), 6.18-6.21 (m, 1H), 7.18-7.23 (m, 3H), 7.35-7.39 (m , 2H), 7.54 (s, 1H),11.55 (s, 1H) ; MS, *m/e* 565.98 (M+1)$^+$
64	Ph	H	H	Me	c-Pr-CH_2-	^{1}H NMR (DMSO-d_6) δ 0.20-0.24(m, 2H), 0.47-0.48(m, 2H), 0.76-0.84(m, 3H), 1.03-1.05(m, 1H), 1.23(dd, *J= 22.4 6.8 Hz* 3H), 1.55-1.60(m, 2H), 3. 61-3.68(m, 1H), 3. 81-3.89 (m, 3H), 3.98-4.03(m, 1H), 4.23-4.29(m, 1H), 4.35-4.41(m, 1H), 5.56-6.00(m, 1H)，5.88-5.91(m, 1H), 6.04-6.10(m, 2H), 7.20-7.24(m, 4H), 7.55 (d, *J= 7.6 Hz* 1H),11.53 (s, 1H) ; MS, *m/e* 573.17 (M+1)$^+$
65	Ph	H	H	Et	c-Pen	^{1}H NMR (DMSO-d_6) δ 0.75-0.83 (m, 3H), 1.20-1.28 (m, 3H), 1.49-1.63 (m, 8H), 1.76-1.80 (m, 2H), 3.58-3.60 (m, 1H), 3.70-3.82 (m, 1H), 3.98-4.05 (m, 1H), 4.24-4.26 (m, 1H)，4.37-4.42 (m, 1H), 5.03 (s, 1H), 5.54-5.57 (m, 1H), 5.90-6.00 (m,1H), 6.02-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.35-7.39 (m, 2H) 7.55 (d, *J* = 8.0 Hz, 1H), 11.55 (s, 1H) ; MS, *m/e* 570.03 (M+1)$^+$

*R^2 and R^{3b} together are $-(CH_2)_3-$ as derived from L-proline

The purification procedure by Prep-HPLC:

Crude products were dissolved in methanol. Injection volumes of these solutions were 5 mL.

Gilead Exhibit 2029
PGR2023-00046 - Page 002030

The preparative HPLC system including 2 sets of Gilson 306 pumps, a Gilson 156 UV/Vis detector, a Gilson 215 injector & fraction collector, with Unipoint control software. A Ymc 25×30×2 mm column was used. The mobile phase was HPLC grade water (A), and HPLC grade acetonitrile (B). Fractions were collected into 100*15mm glass tubes.


HPLC gradient is shown in Table 1. Once the gradient was selected, acetonitrile solution was injected into HPLC system, and then fractions collected according to UV peaks. After the separation, each glass tubes were run MS test to collect the desired compounds. The fractions with target MS were combined in a well-weighted flask. Most of acetonitrile was removed under reduce pressure and the remaining solution was freeze-dried to give desired compound.

Table 1:

Preparative HPLC gradient			
Time (min)	Flow rate (mL/min)	% A	% B
0	15	90	10
30	15	60	40

Preparation of Example 66

Scheme



Preparation of compound (b)

To a solution of compound **a** (1 g, 2.69 mmol) in anhydrous THF (30 mL) was added dropwise 1 M solution of LiAl(OBu-*t*)$_3$H in THF (2.69 mL, 2. 69 mmol) at -20 °C. The reaction mixture was stirred for 2-3 h at the same temperature. EtOAc (100 mL) was added followed by saturated NH_4Cl solution (10 mL) and reaction mixture was slowly brought to room temperature. Reaction mixture was extracted with EtOAc and washed with 1N HCl and water. Combined organic phase was evaporated to give 0.8 g of crude compound **b** as transparent oil, which was used directly for next reaction.

Preparation of compound (d)

To a solution of compound **b** (0.8 g, 2.1mmol), compound **c** (0.45 g, 2.5 mmol) and Ph_3P (0.56 g, 2.1 mmol) in anhydrous THF (20 mL) under nitrogen atmosphere was added DEAD (1.8 mL). The reaction mixture was stirred at room temperature overnight.

Gilead Exhibit 2029
PGR2023-00046 - Page 002032

The reaction solution was concentrated under reduce pressure. The residue was separated by preparative layer chromatography (hexanes:EtOAc = 3:1) to give crude compound **d** (0.8 g). The crude compound **d** was used to the next step without further purification.

Preparation of compound (e)

Compound **d** (0.8 g, 1.57 mmol) was dissolved in THF (2 mL) and THF saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was heated to 90 °C overnight. After 18 hours, the solution was cooled to room temperature by ice water, then the solvent was removed under reduced pressure and the residue was purified by column to give compound **e** (0.75 g) for the next step.

Preparation of compound (f)

Compound **e** (0.5 g, 1.01 mmol) was dissolved in methanol (2 mL) and methanol was saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was stirred at room temperature overnight. After 18 hours, the solvent was removed under reduced pressure and the residue was purified by column to give crude compound **f** (0.15 g) for the next step.

Preparation of compound (i)

A solution of triethylamine (1.07 g, 10.6 mmol) in anhydrous dichloromethane (15 mL) was added dropwise to a solution of compound **g** (1.16 g, 5.3 mmol) and compound **h** (1.31 g, 5.3 mmol) in dichloromethane (10 mL) with vigorous stirring at -78 °C over a period of 2 hours. After completion of addition, the reaction temperature was allowed to warm to room temperature gradually and stirred over night. Then the solvent was removed under vacuum and anhydrous ether 20 mL was added and the precipitated salt was filtered and the precipitate was washed with ether. The combined organic phase was concentrated to give the colorless oil of compound **i** (1.0 g).


Preparation of Compound 66


To a solution of compound **j** (0.1 g, 0.35 mmol) dissolved in 10 mL of anhydrous THF, stirred and added 0.4g NMI till the solution became clear, added compound **i** (0.8 g, 2.89 mmol) in 10 mL THF dropwise, stirred at r.t. overnight. Compound purity and identification was confirmed by LCMS. The solvent was evaporated and purified by Prep-HPLC to afford **66**. (25 mg, Yield: 13.6%). ^{1}H NMR (DMSO-d_6) δ 1.08 (d, J =

Gilead Exhibit 2029
PGR2023-00046 - Page 002033


22.8 Hz, 3H), 1.17-1.24 (m, 3H), 3.50-3.52 (m, 3H), 3.78-3.83 (m, 1H), 4.10-4.13 (m, 1H), 4.24-4.44 (m, 2H), 5.85-5.92 (m, 1H), 6.01-6.11 (m,1H), 6.2.-6.27 (m, 1H), 7.08-7.19 (m, 4H), 7.31-7.38 (m, 3H), 8.15 (s, 1H), 8.26 (s, 1H); MS, *m/e* 525 $(M+1)^+$.

Example numbers **67-74**, identified below, were prepared using similar procedures disclosed for Example **66**, above.




Example	R^{11}	R^{10}	NMR/MS
67	OH	NH_2	^{1}H NMR (DMSO-d_6) δ 1.06-1.13 (m, 3H), 1.20-1.24 (m, 3H), 3.27-3.33(m, 3H), 3.56 (s, 1H), 3.82-3.88 (m, 1H), 4.07-4.13 (m, 1H), 4.25-4.40 (m, 2H), 5.85-5.87 (m, 1H), 5.98-6.09 (m, 2H), 6.59 (s, 32H), 7.14-7.37 (m, 3H), 7.35-7.37 (m, 2H), 7.79 (d, *J*=7.2 Hz, 1H), 10.69 (s, 1H); MS, *m/e* 541 $(M+1)^+$;
68	NH_2	NH_2	^{1}H NMR (DMSO-d_6) δ 1.07 (d, *J*=22.8 Hz, 3H), 1.19 (d, *J*=7.2 Hz, 3H), 3.51 (s, 3H), 3.62 (s, 1H), 3.75-3.81 (m, 1H), 4.05-4.11 (m, 1H), 4.27-4.42 (m, 2H), 5.79-5.83 (m, 1H), 5.92 (s, 2H), 6.00-6.09 (m, 2H), 6.75 (s, 2H), 7.08-7.17 (m, 3H), 7.31-7.35 (m, 2H), 7.78 (s, 1H); MS, *m/e* 540 $(M+1)^+$;
69	NH_2	c-Pentyl-NH-	^{1}H NMR (DMSO-d_6) δ 1.05 (d, *J*=22.8 Hz, 3H), 1.09-1.19 (m, 3H), 1.48 (s, 4H), 1.66 (s, 1H), 1.86 (s, 1H), 3.54 (d, *J*=14 Hz, 3H), 3.65 (s, 1H), 4.25-4.43 (m, 4H), 5.71-5.82 (m, 1H), 5.94-6.04 (m, 4H), 7.11-7.24 (m, 3H), 7.26-7.34 (m, 2H), 7.77(d, *J*=3.6 Hz, 1H); MS, *m/e* 608$(M+1)^+$
70	NH_2		^{1}H NMR (DMSO-d_6) δ 1.07 (d, *J*=22.4 Hz, 3H), 2.35-2.38 (m, 2H), 3.54 (d, *J*=9.2 Hz, 3H), 3.59-3.62 (m, 2H), 3.65 (s, 1H), 3.75-3.82 (m, 1H), 4.01-4.13 (m, 2H), 4.22-4.40 (m, 6H), 5.75-5.85 (m, 1H), 6.00-6.07 (m, 4H), 7.15-7.21 (m, 3H), 7.32-7.35 (m, 2H), 7.79 (d, *J*=4.0 Hz, 1H); MS, *m/e* 580 $(M+1)^+$
71	NH_2	Et_2N-	^{1}H NMR (DMSO-d_6) δ 1.06-1.28 (m, 12H), 3.55 (d, *J*=4.8



Gilead Exhibit 2029
PGR2023-00046 - Page 002034

Example	R^{11}	R^{10}	NMR/MS
			Hz, 3H), 3.79-3.87 (m, 4H), 4.07-4.12 (m, 2H), 4.29-4.42 (m, 3H), 5.75-5.82 (m, 1H), 5.94 (s, 2H), 6.04-6.10 (m, 2H), 7.14-7.22 (m, 3H), 7.31-7.37 (m, 2H), 7.82 (d, *J*=4.4 Hz, 1H); MS, *m/e* 596 $(M+1)^+$
72	NH_2	n-Propyl-NH-	^{1}H NMR (DMSO-d_6) δ 0.84 (t, *J*=7.2 Hz, 3H), 1.01-1.01 (m, 3H), 1.09-1.12 (m, 3H), 1.51-1.56 (m, 2H), 3.48 (d, *J*=15.2 Hz, 3H), 3.79-3.82 (m, 1H), 4.04-4.05 (m, 1H), 4.27-4.38 (m, 3H), 5.72-5.79 (m, 1H), 5.98-6.04 (m, 4H), 7.13-7.20 (m, 3H), 7.26-7.32 (m, 2H), 7.76 (d, *J*=5.2 Hz, 1H); MS, *m/e* 582 $(M+1)^+$
73	NH_2	c-Butyl-NH-	^{1}H NMR (DMSO-d_6) δ 1.02-1.08 (m, 3H), 1.18 (d, *J*=4.8 Hz, 3H), 1.44-1.61 (m, 2H)，2.02-2.17 (m, 4H), 3.51 (d, *J*=10.8 Hz, 3H), 3.78-3.83 (m, 1H), 4.03-4.06 (m, 1H), 4.27-4.38 (m, 2H), 4.53-4.62 (m, 1H), 5.68-5.79 (m, 1H), 5.95-6.04 (m, 4H), 7.11-7.18 (m, 3H), 7.29-7.35 (m, 2H), 7.51-7.58 (m, 1H), 7.78 (d, *J*=5.2 Hz, 1H); MS, *m/e* 594 $(M+1)^+$
74	NH_2		^{1}H NMR (DMSO-d_6) δ 0.97-1.20 (m, 6H), 2.18 (s, 3H), 2.19 (s, 4H), 3.43-3.47(m, 3H), 3.75 (s, 1H), 4.01-4.06 (m, 4 H), 4.22-4.35 (m, 3H), 5.69-5.75 (m, 1H), 5.98-6.05 (m, 3H), 7.09-7.15 (m, 3H), 7.25-7.29 (m, 2H), 7.77 (d, *J*=3.6 Hz, 1H); MS, *m/e* 623 $(M+1)^+$

Example numbers 75-80 are prepared using similar procedures disclosed for Example **66**, above.



Gilead Exhibit 2029
PGR2023-00046 - Page 002035

Example	R^{11}	R^{10}
75	H	n-propyl-NH-
76	H	c-Butyl-NH-
77	H	c-Pentyl-NH-
78	H	
79	H	
80	H	

EXAMPLE 81

Certain exemplified compounds were obtained as mixture of diastereomers because of the chirality at phosphorous. The diastereomers were separated on a Chiralpak-AS-H (2 X 25 cm) column under Supercritical Fluid Chromatography (SFC) conditions using 20% methanol in carbon dioxide as solvent. The absolute stereochemistry of the P-chiral center of the diastereromers were not determined. However, chromatographic resolution of these two diastereomers provides for isomers that are characterized as fast eluting and slow eluting isomers. Some examples are shown below.

Compound	**EC90 (uM)**
Example 15 (Diastereomeric mixture)	0.86
Fast Moving isomer of **Example 15**	1.35
Slow Moving isomer of **Example 15**	0.26
Example 39 (Diastereomeric mixture)	0.47
Fast Moving isomer of **Example 39**	0.78
Slow Moving isomer of **Example 39**	0.02

Compound	EC90 (uM)
Example 49 (Diastereomeric mixture)	0.126
Fast Moving isomer of **Example 49**	0.03
Slow Moving isomer of **Example 49**	5.78








EXAMPLE 82

HCV replicon assay. HCV replicon RNA-containing Huh7 cells (clone A cells; Apath, LLC, St. Louis, Mo.) were kept at exponential growth in Dulbecco's modified Eagle's medium (high glucose) containing 10% fetal bovine serum, 4 mM L-glutamine and 1 mM sodium pyruvate, 1× nonessential amino acids, and G418 (1,000 μg/ml). Antiviral assays were performed in the same medium without G418. Cells were seeded in a 96-well plate at 1,500 cells per well, and test compounds were added immediately after seeding. Incubation time 4 days. At the end of the incubation step, total cellular RNA was isolated (RNeasy 96 kit; Qiagen). Replicon RNA and an internal control (TaqMan rRNA control reagents; Applied Biosystems) were amplified in a single-step multiplex RT-PCR protocol as recommended by the manufacturer. The HCV primers and probe were designed with Primer Express software (Applied Biosystems) and covered highly conserved 5′-untranslated region (UTR) sequences (sense, 5′-AGCCATGGCGTTAGTA(T)GAGTGT-3′, and antisense, 5′-TTCCGCAGACCACTATGG-3′; probe, 5′-FAM-CCTCCAGGACCCCCCCTCCC-TAMRA-3′).







To express the antiviral effectiveness of a compound, the threshold RT-PCR cycle of the test compound was subtracted from the average threshold RT-PCR cycle of the no-drug control (ΔCt_{HCV}). A ΔCt of 3.3 equals a 1-log 10 reduction (equal to the 90% effective concentration [EC_{90}]) in replicon RNA levels. The cytotoxicity of the test compound could also be expressed by calculating the ΔCt_{rRNA} values. The ΔΔCt specificity parameter could then be introduced ($\Delta Ct_{HCV} - \Delta Ct_{rRNA}$), in which the levels of







Gilead Exhibit 2029
PGR2023-00046 - Page 002037

HCV RNA are normalized for the rRNA levels and calibrated against the no-drug control.

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
5		-1.21	3.0
6		-0.45	ND
7		0.31	ND
8		-1.48	2.11
10		-1.25	19.15
11		-0.55	ND
12		0.31	ND

Gilead Exhibit 2029
PGR2023-00046 - Page 002038

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
15		ND	0.86
25		-2.22	0.39
27		-2.25	0.66
28		-2.16	0.75
36		-1.64	21.9
39		-1.78	0.47

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
49		-2.69	0.126
53		-1.33	<0.3
54		-1.55	0.57
55		-2.38	<0.3
69		-2.25	< 0.3
70		-2.25	<0.3

[1](4-BrPh): 4-bromo-phenyl.

Gilead Exhibit 2029
PGR2023-00046 - Page 002040

The entire contents of U.S. Provisional Application Nos. 60/909,315, filed March 30, 2007, and 60/982,309, filed October 24, 2007, are hereby incorporated by reference in the present application so far as needed to supplement the present disclosure and/or rectify any errors. Moreover, the patent and non-patent references disclosed herein are incorporated by reference. In the event that the incorporated patent and non-patent reference contains a term that conflicts with a term disclosed in either one of the two Provisional Applications or the present application text, the meaning of the term contained in the present application text and the two Provisional Applications controls provided that the overall meaning of the incorporated subject matter is not lost.

Gilead Exhibit 2029
PGR2023-00046 - Page 002041

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/077,267	10/22/2020	Jinfa Du	37JD-199059-US13	4237

117796 7590 01/20/2023

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
650 Town Center Drive, 10th Floor
Costa Mesa, CA 92626

EXAMINER	
LEWIS, PATRICK T	

ART UNIT	PAPER NUMBER
1623	

NOTIFICATION DATE	DELIVERY MODE
01/20/2023	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

SheppardMullin_Pair@firsttofile.com
ipdocketing@gilead.com
svipdocketing@sheppardmullin.com

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Application No. : 17077267
Applicant : Du
Filing Date : 10/22/2020
Date Mailed : 01/20/2023

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Notice of Allowance Mailed

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

Applicant is given two (2) months from the mail date of this Notice within which to respond. This time period for reply is extendable under 37 CFR 1.136(a) for only TWO additional MONTHS.

The informalities requiring correction are indicated in the attachment(s). If the informality pertains to the abstract, specification (including claims) or drawings, the informality must be corrected with an amendment in compliance with 37 CFR 1.121 (or, if the application is a reissue application, 37 CFR 1.173). Such an amendment may be filed after payment of the issue fee if limited to correction of informalities noted herein. See Waiver of 37 CFR 1.312 for Documents Required by the Office of Patent Publication, 1280 Off. Gaz. Patent Office 918 (March 23, 2004). In addition, if the informality is not corrected until after payment of the issue fee, for purposes of 35 U.S.C. 154(b)(1)(iv), "all outstanding requirements" will be considered to have been satisfied when the informality has been corrected. A failure to respond within the above-identified time period will result in the application being ABANDONED.

See attachment(s).

A copy of this notice MUST be returned with the reply. Please address response to "Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450".

/June Hope/
Publication Branch
Office of Data Management
(571) 272-4200

Application No. 17077267

IDENTIFICATION OF APPLICATION DEFICIENCIES
IN APPLICATION FILED ON OR AFTER SEPTEMBER 16, 2012

[X] Applicant must provide legible text for the following item(s).

- [X] Specification filed 10/22/2020, page(s) (see below).
- [ ] Claims filed , claim(s) .
- [ ] Other: .

[ ] Applicant must provide missing information on the following page(s) of the specification by amending the specification to add the missing text. No new matter may be added.
Page/line no(s).

[ ] The specification refers to one or more applications by attorney docket number and does not show the U.S. application number(s). Applicant must supply the U.S. application number in place of each attorney docket number.
Page/line no(s).

[ ] Applicant must provide an Abstract of the Disclosure.

[ ] The Application Data Sheet (ADS dated) does not supply the inventor's city and/or does not supply the inventor's U.S. state and/or does not supply the inventor's country. Applicant must submit a signed, in accordance with 37 CFR 1.76(e) and 1.33(b), application data sheet that corrects this deficiency. To be in compliance with 37 CFR 1.76, the corrected application data sheet must identify the information being changed by using underlining for additions and strikethroughs or brackets for deletions.

[X] Other: The following Spec pages contain overlapping and/or obscured data: Pages 116, 133, 151, 169, 186, 204, 221, 238, 256, 273, 291, 308, 326, 343, 360, 378, 395, 413, 430, 447, 465, 482, 499, 517, 534, 551, 568, 585, 602, 620 and 637.

The response to this notice should contain only amended papers, as the waiver of 37 CFR 1.312 is limited to corrections of documents specifically requested in the notice.

Docket No.: 37JD-199059-US13
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gilead Sciences, Inc.

Application No.: 17/077,267	Confirmation No.: 4237
Filed: October 22, 2020	Art Unit: 1623
For: NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS	Examiner: Patrick T. Lewis

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

In response to the Notice to File Corrected Application Papers mailed January 20, 2023 (hereinafter "the Notice"), in the above-identified patent application, Applicant submits an amendment to the specification in compliance with 37 C.F.R. § 1.121 to complete the filing of the subject patent application. The Office set forth a two month period to reply to the Notice. Accordingly, this reply is timely filed before its due date of March 20, 2023.

The Notice requests legible text for pages 116, 133, 151, 169, 186, 204, 221, 238, 256, 273, 291, 308, 326, 343, 360, 378, 395, 413, 430, 447, 465, 482, 499, 517, 534, 551, 568, 585, 602, 620, and 637 of the specification filed on October 22, 2020.

In response, Applicant submits herewith a Substitute Specification pursuant to 37 C.F.R. §1.125 with legible text as requested by the Office. No "Marked-up Copy of Substitute Specification" is provided as the only changes relative to the immediate prior version of the specification of record (which includes the amendments as filed in the Amendment and Reply to

Non-Final Office Action under 37 C.F.R. § 1.111, dated July 12, 2022, and Preliminary Amendment under 37 C.F.R. § 1.115, dated October 22, 2020) is to provide legible text.

Specifically, the tables numbered "43" on the pages listed above no longer contain overprints in the right hand side of the table. Applicant respectfully submits that the overprints were merely typographical errors pertaining to line numbering on the pages listed above and would have been readily recognizable as such.

No new matter is added by virtue of this amendment; thus, entry thereof is respectfully requested.

It is believed that no fees are due in connection with the submission of these papers.

Respectfully submitted,

Dated: February 15, 2023

By /Joy Lynn Nemirow/
Joy Lynn Nemirow, Ph.D.
Registration No.: 67,163
Attorney for Applicant
SHEPPARD MULLIN RICHTER & HAMPTON LLP
650 Town Center Drive, 10th Floor
Costa Mesa, CA 92626
(650) 815-2634
Customer Number: 117796

Gilead Exhibit 2029
PGR2023-00046 - Page 002046

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/077,267	**02/15/2023 07:05:15 PM ET**	**37JD-199059-US13**

Title of Invention

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	4237	FILED BY	Joannah Laluces
PATENT CENTER #	61602516	FILING DATE	10/22/2020
CUSTOMER #	117796	FIRST NAMED INVENTOR	Jinfa Du
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Joy Nemirow

Documents

TOTAL DOCUMENTS: 8

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
37JD-199059-US13_SpecificationPart1.pdf	226	Specification	931 KB
37JD-199059-US13_SpecificationPart2.pdf	224	Specification	885 KB
37JD-199059-US13_SpecificationPart3.pdf	110	Specification	464 KB
37JD-199059-US13_SpecificationPart4.pdf	50	Specification	274 KB
37JD-199059-US13_SpecificationPart5.pdf	45	Specification	324 KB

37JD-199059-US13_SpecificationPart6.pdf	6	Specification	168 KB
37JD-199059-US13_SpecificationPart7.pdf	17	Specification	118 KB
37JD-199059-US13_Response_to_Notice_to_File_Corrected_Application_Papers.pdf	5	Applicant Response to Pre-Exam Formalities Notice	208 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
37JD-199059-US13_SpecificationPart1.pdf	0D661E611BB4AE05B262C37D070CC1ED63182CCF4FF84AAA84FAFDE340EED94EF6BE74C6A1F93953CE8E8A29B1C93EBEC765AEA5E9B99D1F7A1771FEAF613981
37JD-199059-US13_SpecificationPart2.pdf	874264CF74EA18C53A76AE4937B995A4E7D205B772DD6424CBE4A8ABFC5937D878EE250CDA8C03C6E2C4975F0EEF9ECF8D508322A1184E281318E6F46D107DF7
37JD-199059-US13_SpecificationPart3.pdf	1858E2593A57BB201E40ADFD051B01BCAEE243769C5B3A2BC62ACE98F87C4A12D086963CE9A018FCDE57C61DC6428346D9D8632F095D77FB918CCD668CBAEE79
37JD-199059-US13_SpecificationPart4.pdf	EFC185DDBD7AF132E5947640AB4378942E77405A35FCA401E45B6ABAC2DF8934376049AD3C8BB358405C968244429B76A84F1701035830B104814CB52A1AAA22
37JD-199059-US13_SpecificationPart5.pdf	C41F60D7E8F4BEA16770A8A9CC4F0D02BEE67342287D011B6640572FA93FF57E4985C33E68F6A6B67045D4106C9D379CC1289AE0B9557AB8A147F76591AC5679
37JD-199059-US13_SpecificationPart6.pdf	4D5E12EAF9B2A1B669CEDA642FF481DE0668697E7D9392525AA76899BE23C0E3924102D55E26221BA3835F7BD9C29276258D9AE84D2648FB8754100DC2E41285

37JD-199059-US13_SpecificationPart7.pdf	A66E7F6D43BDCFCE80C3FED06FB6ED922082F93F0D362BD1D24C8C664244E175DB9755D0BA26C708A15452521195062BFDC682E87AB0E208CC3E8E39C5512EC1
37JD-199059-US13_Response_to_Notice_to_File_Corrected_Application_Papers.pdf	5F0108C2F8A52A6A56907EF15950C8929563C6C5CEC555495B6E9F481ABBF95354D74B120D48CC58883103E3200E9EF70013F134CBB249DF0A1577664AC7F7D2

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/077,267	10/22/2020	Jinfa Du	37JD-199059-US13	4237

117796 7590 03/06/2023

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
650 Town Center Drive, 10th Floor
Costa Mesa, CA 92626

EXAMINER	
LEWIS, PATRICK T	

ART UNIT	PAPER NUMBER
1623	

NOTIFICATION DATE	DELIVERY MODE
03/06/2023	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

SheppardMullin_Pair@firsttofile.com
ipdocketing@gilead.com
svipdocketing@sheppardmullin.com

Response to Rule 312 Communication	Application No.	Applicant(s)	
	17/077,267	Du et al.	
	Examiner	Art Unit	AIA (FITF) Status
	PATRICK T LEWIS	1623	No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☑ The amendment filed on 15 February 2023 under 37 CFR 1.312 has been considered, and has been:

a) ☑ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.
Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☐ entered in part. See explanation below.

f) ☐ not entered because the supplemental or corrected Application Data sheet (ADS)

☐ was not accompanied by a petition to accept an unintentionally delayed claim under 37 CFR 1.55 or 27 CFR 1.78;

☐ did not identify the information being changed in accordance with 37 CFR 1.76(c)(2);

☐ was not properly signed in accordance with 37 CFR 1.76(e) (or 37 CFR 1.33(b) for applications filed prior to September 16, 2012).

/PATRICK T LEWIS/
Primary Examiner, Art Unit 1623

Gilead Exhibit 2029
PGR2023-00046 - Page 002051

OK TO ENTER: /P.T.L/

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Patent Application No. 16/817,318, filed March 12, 2020, now abandoned, which is a continuation of U.S. Patent Application No. 16/516,192, filed July 18, 2019, now abandoned, which is a continuation of U.S. Patent Application No. 16/169,878, filed October 24, 2018, now abandoned, which is a continuation of U.S. Patent Application No. 15/411,506, filed January 20, 2017, now U.S. Patent No. 10,183,037, which is a continuation of U.S. Patent Application No. 14/656,546, filed March 12, 2015, now U.S. Patent No. 9,585,906, which is a continuation of U.S. Patent Application No. 14/013,237, filed August 29, 2013, now U.S. Patent No. 9,085,573, which is a continuation of U.S. Patent Application No. 13/609,614, filed September 11, 2012, now U.S. Patent No. 8,580,765, which is a continuation of U.S. Patent Application No. 13/099,671, filed May 3, 2011, now U.S. Patent No. 8,334,270, which is a continuation of U.S. Patent Application No. 12/053,015, filed March 21, 2008, now U.S. Patent No. 7,964,580, which claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application Nos. 60/909,315, filed March 30, 2007, and 60/982,309, filed October 24, 2007, all of which are hereby incorporated by reference in their entireties.

Sequence Listing

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety.

Field of Invention

The present invention pertains to nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. The invention provides novel chemical compounds, and the use of these compounds alone or in combination with other antiviral agents for treating HCV infection.

Background

Hepatitis C virus (HCV) infection is a major health problem that leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals, estimated to be 2-15% of the world's population. There are an estimated 4.5 million infected people in the United States alone, according to the U.S. Center for Disease Control. According to the World Health Organization, there are more than 200 million infected individuals worldwide, with at least 3 to 4 million people being infected each year. Once infected, about 20% of people clear the virus, but the rest can harbor HCV the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or cancer. The viral disease is transmitted parenterally by contaminated blood and blood products, contaminated needles, or sexually and vertically from infected mothers or carrier mothers to their offspring. Current treatments for HCV infection, which are restricted to immunotherapy with recombinant interferon-α alone or in combination with the nucleoside analog ribavirin, are of limited clinical benefit. Moreover, there is no established vaccine for

Gilead Exhibit 2029
PGR2023-00046 - Page 002053

HCV. Consequently, there is an urgent need for improved therapeutic agents that effectively combat chronic HCV infection.

The HCV virion is an enveloped positive-strand RNA virus with a single oligoribonucleotide genomic sequence of about 9600 bases which encodes a polyprotein of about 3,010 amino acids. The protein products of the HCV gene consist of the structural proteins C, E1, and E2, and the non-structural proteins NS2, NS3, NS4A and NS4B, and NS5A and NS5B. The nonstructural (NS) proteins are believed to provide the catalytic machinery for viral replication. The NS3 protease releases NS5B, the RNA-dependent RNA polymerase from the polyprotein chain. HCV NS5B polymerase is required for the synthesis of a double-stranded RNA from a single-stranded viral RNA that serves as a template in the replication cycle of HCV. Therefore, NS5B polymerase is considered to be an essential component in the HCV replication complex (K. Ishi, et al, *Heptology*, 1999, 29: 1227-1235; V. Lohmann, et al., *Virology*, 1998, 249: 108-118). Inhibition of HCV NS5B polymerase prevents formation of the double-stranded HCV RNA and therefore constitutes an attractive approach to the development of HCV-specific antiviral therapies.

HCV belongs to a much larger family of viruses that share many common features.

Flaviviridae Viruses

The Flaviviridae family of viruses comprises at least three distinct genera: *pestiviruses*, which cause disease in cattle and pigs; *flavivruses*, which are the primary cause of diseases such as dengue fever and yellow fever; and *hepaciviruses*, whose sole

Gilead Exhibit 2029
PGR2023-00046 - Page 002054

member is HCV. The flavivirus genus includes more than 68 members separated into groups on the basis of serological relatedness (Calisher et al., *J. Gen. Virol*, 1993,70,37-43). Clinical symptoms vary and include fever, encephalitis and hemorrhagic fever (*Fields Virology*, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, PA, 1996, Chapter 31, 931-959). Flaviviruses of global concern that are associated with human disease include the Dengue Hemorrhagic Fever viruses (DHF), yellow fever virus, shock syndrome and Japanese encephalitis virus (Halstead, S. B., *Rev. Infect. Dis.*, 1984, 6, 251-264; Halstead, S. B., *Science*, 239:476-481, 1988; Monath, T. P., *New Eng. J. Med*, 1988, 319, 64 1-643).

The pestivirus genus includes bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, also called hog cholera virus) and border disease virus (BDV) of sheep (Moennig, V. et al. *Adv. Vir. Res.* 1992, 41, 53-98). Pestivirus infections of domesticated livestock (cattle, pigs and sheep) cause significant economic losses worldwide. BVDV causes mucosal disease in cattle and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, H.J., Advances in Virus Research, 1996, 47, 53-118; Moennig V., et al, Adv. Vir. Res. 1992, 41, 53-98). Human pestiviruses have not been as extensively characterized as the animal pestiviruses. However, serological surveys indicate considerable pestivirus exposure in humans.

Pestiviruses and hepaciviruses are closely related virus groups within the Flaviviridae family. Other closely related viruses in this family include the GB virus A, GB virus A-like agents, GB virus-B and GB virus-C (also called hepatitis G virus, HGV). The hepacivirus group (hepatitis C virus; HCV) consists of a number of closely related but genotypically distinguishable viruses that infect humans. There are at least 6 HCV

Gilead Exhibit 2029
PGR2023-00046 - Page 002055

genotypes and more than 50 subtypes. Due to the similarities between pestiviruses and hepaciviruses, combined with the poor ability of hepaciviruses to grow efficiently in cell culture, bovine viral diarrhea virus (BVDV) is often used as a surrogate to study the HCV virus.

The genetic organization of pestiviruses and hepaciviruses is very similar. These positive stranded RNA viruses possess a single large open reading frame (ORF) encoding all the viral proteins necessary for virus replication. These proteins are expressed as a polyprotein that is co- and post-translationally processed by both cellular and virus-encoded proteinases to yield the mature viral proteins. The viral proteins responsible for the replication of the viral genome RNA are located within approximately the carboxy-terminal. Two-thirds of the ORF are termed nonstructural (NS) proteins. The genetic organization and polyprotein processing of the nonstructural protein portion of the ORF for pestiviruses and hepaciviruses is very similar. For both the pestiviruses and hepaciviruses, the mature nonstructural (NS) proteins, in sequential order from the amino-terminus of the nonstructural protein coding region to the carboxy-terminus of the ORF, consist of p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B.

The NS proteins of pestiviruses and hepaciviruses share sequence domains that are characteristic of specific protein functions. For example, the NS3 proteins of viruses in both groups possess amino acid sequence motifs characteristic of serine proteinases and of helicases (Gorbalenya et al., *Nature,* 1988, 333, 22; Bazan and Fletterick *Virology* , 1989,171,637-639; Gorbalenya et al., *Nucleic Acid Res.,*1989, 17, 3889-3897). Similarly, the NS5B proteins of pestiviruses and hepaciviruses have the motifs

Gilead Exhibit 2029
PGR2023-00046 - Page 002056

characteristic of RNA-directed RNA polymerases (Koonin, E.V. and Dolja, V.V., *Crir. Rev. Biochem. Molec. Biol.* 1993, 28, 375-430).

The actual roles and functions of the NS proteins of pestiviruses and hepaciviruses in the lifecycle of the viruses are directly analogous. In both cases, the NS3 serine proteinase is responsible for all proteolytic processing of polyprotein precursors downstream of its position in the ORF (Wiskerchen and Collett, *Virology*, 1991, 184, 341-350; Bartenschlager et al., *J. Virol.* 1993, 67, 3835-3844; Eckart et al. *Biochem. Biophys. Res. Comm.* 1993,192, 399-406; Grakoui et al., *J. Virol.* 1993, 67, 2832-2843; Grakoui et al., *Proc. Natl. Acad Sci. USA* 1993, 90, 10583-10587; Hijikata et al., *J. Virol.* 1993, 67, 4665-4675; Tome et al., *J. Virol.*, 1993, 67, 4017-4026). The NS4A protein, in both cases, acts as a cofactor with the NS3 serine protease (Bartenschlager et al., *J. Virol.* 1994, 68, 5045-5055; Failla et al., *J. Virol.* 1994, 68, 3753-3760; Xu et al., *J. Virol.*, 1997, 71:53 12-5322). The NS3 protein of both viruses also functions as a helicase (Kim et al., *Biochem. Biophys. Res. Comm.*, 1995, 215, 160-166; Jin and Peterson, *Arch. Biochem. Biophys.*, 1995, 323, 47-53; Warrener and Collett, *J. Virol.* 1995, 69,1720-1726). Finally, the NS5B proteins of pestiviruses and hepaciviruses have the predicted RNA-directed RNA polymerases activity (Behrens et al., EMBO, 1996, 15, 12-22; Lechmann et al., *J. Virol.*, 1997, 71, 8416-8428; Yuan et al., *Biochem. Biophys. Res. Comm.* 1997, 232, 231-235; Hagedorn, PCT WO 97/12033; Zhong et al, *J. Virol.,* 1998, 72, 9365-9369).

Currently, there are limited treatment options for individuals infected with hepatitis C virus. The current approved therapeutic option is the use of immunotherapy with recombinant interferon-α alone or in combination with the nucleoside analog

Gilead Exhibit 2029
PGR2023-00046 - Page 002057

ribavirin. This therapy is limited in its clinical effectiveness and only 50% of treated patients respond to therapy. Therefore, there is significant need for more effective and novel therapies to address the unmet medical need posed by HCV infection.

A number of potential molecular targets for drug development of direct acting antivirals as anti -HCV therapeutics have now been identified including, but not limited to, the NS2-NS3 autoprotease, the N3 protease, the N3 helicase and the NS5B polymerase. The RNA-dependent RNA polymerase is absolutely essential for replication of the single-stranded, positive sense, RNA genome and this enzyme has elicited significant interest among medicinal chemists.

Inhibitors of HCV NS5B as potential therapies for HCV infection have been reviewed: Tan, S.-L., et al., *Nature Rev. Drug Discov.*, 2002, 1, 867-881; Walker, M.P. et al., *Exp. Opin. Investigational Drugs*, 2003, 12, 1269-1280; Ni, Z-J., et al., *Current Opinion in Drug Discovery and Development*, 2004, 7, 446-459; Beaulieu, P. L., et al., *Current Opinion in Investigational Drugs*, 2004, 5, 838-850; Wu, J., et al., *Current Drug Targets-Infectious Disorders*, 2003, 3, 207-219; Griffith, R.C., et al, *Annual Reports in Medicinal Chemistry*, 2004, 39, 223-237; Carrol, S., et al., *Infectious Disorders-Drug Targets*, 2006, 6, 17-29. The potential for the emergence of resistant HCV strains and the need to identify agents with broad genotype coverage supports the need for continuing efforts to identify novel and more effective nucleosides as HCV NS5B inhibitors.

Nucleoside inhibitors of NS5B polymerase can act either as a non-natural substrate that results in chain termination or as a competitive inhibitor which competes with nucleotide binding to the polymerase. To function as a chain terminator the

Gilead Exhibit 2029
PGR2023-00046 - Page 002058

nucleoside analog must be taken up by the cell and converted *in vivo* to a triphosphate to compete for the polymerase nucleotide binding site. This conversion to the triphosphate is commonly mediated by cellular kinases which imparts additional structural requirements on a potential nucleoside polymerase inhibitor. Unfortunately, this limits the direct evaluation of nucleosides as inhibitors of HCV replication to cell-based assays capable of *in situ* phosphorylation.

In some cases, the biological activity of a nucleoside is hampered by its poor substrate characteristics for one or more of the kinases needed to convert it to the active triphosphate form. Formation of the monophosphate by a nucleoside kinase is generally viewed as the rate limiting step of the three phosphorylation events. To circumvent the need for the initial phosphorylation step in the metabolism of a nucleoside to the active triphosphate analog, the preparation of stable phosphate prodrugs has been reported. Nucleoside phosphoramidate prodrugs have been shown to be precursors of the active nucleoside triphosphate and to inhibit viral replication when administered to viral infected whole cells (McGuigan, C., et al., *J. Med. Chem.*, 1996, 39, 1748-1753; Valette, G., et al., *J. Med. Chem.*, 1996, 39, 1981-1990; Balzarini, J., et al., *Proc. National Acad Sci USA*, 1996, 93, 7295-7299; Siddiqui, A. Q., et al., *J. Med. Chem.*, 1999, 42, 4122-4128; Eisenberg, E. J., et al., *Nucleosides, Nucleotides and Nucleic Acids*, 2001, 20, 1091-1098; Lee, W.A., et al., *Antimicrobial Agents and Chemotherapy*, 2005, 49, 1898); US 2006/0241064; and WO 2007/095269.


Also limiting the utility of nucleosides as viable therapeutic agents is their sometimes poor physicochemical and pharmacokinetic properties. These poor properties can limit the intestinal absorption of an agent and limit uptake into the target tissue or

Gilead Exhibit 2029
PGR2023-00046 - Page 002059

cell. To improve on their properties prodrugs of nucleosides have been employed. It has been demonstrated that preparation of nucleoside phosphoramidates improves the systemic absorption of a nucleoside and furthermore, the phosphoramidate moiety of these "pronucleotides" is masked with neutral lipophilic groups to obtain a suitable partition coefficient to optimize uptake and transport into the cell dramatically enhancing the intracellular concentration of the nucleoside monophosphate analog relative to administering the parent nucleoside alone. Enzyme-mediated hydrolysis of the phosphate ester moiety produces a nucleoside monophosphate wherein the rate limiting initial phosphorylation is unnecessary.

SUMMARY OF THE INVENTION

The present invention is directed toward novel phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6}

Gilead Exhibit 2029
PGR2023-00046 - Page 002060

alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

Gilead Exhibit 2029
PGR2023-00046 - Page 002061

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Gilead Exhibit 2029
PGR2023-00046 - Page 002062



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6,

Gilead Exhibit 2029
PGR2023-00046 - Page 002063

halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

DEFINITIONS

The phrase "a" or "an" entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein.

The phrase "as defined herein above" refers to the first definition provided in the Summary of the Invention.

The terms "optional" or "optionally" as used herein means that a subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optional bond" means that the bond may or may not be present, and that the description includes single, double, or triple bonds.

The term "independently" is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R appears twice and is defined as "independently carbon or nitrogen", both R's can be carbon, both R's can be nitrogen, or one R' can be carbon and the other nitrogen.

The term "alkenyl" refers to an unsubstituted hydrocarbon chain radical having from 2 to 10 carbon atoms having one or two olefinic double bonds, preferably one olefinic double bond. The term "$C_{2\text{-}N}$ alkenyl" refers to an alkenyl comprising 2 to N carbon atoms, where N is an integer having the following values: 3, 4, 5, 6, 7, 8, 9, or 10. The term "$C_{2\text{-}10}$ alkenyl" refers to an alkenyl comprising 2 to 10 carbon atoms. The term

Gilead Exhibit 2029
PGR2023-00046 - Page 002064

"C_{2-4} alkenyl" refers to an alkenyl comprising 2 to 4 carbon atoms. Examples include, but are not limited to, vinyl, 1-propenyl, 2-propenyl (allyl) or 2-butenyl (crotyl).

The term "halogenated alkenyl" refers to an alkenyl comprising at least one of F, Cl, Br, and I.

The term "alkyl" refers to an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 30 carbon atoms. The term "C_{1-M} alkyl" refers to an alkyl comprising 1 to M carbon atoms, where M is an integer having the following values: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. The term "C_{1-4} alkyl" refers to an alkyl containing 1 to 4 carbon atoms. The term "lower alkyl" denotes a straight or branched chain hydrocarbon residue comprising 1 to 6 carbon atoms. "C_{1-20} alkyl" as used herein refers to an alkyl comprising 1 to 20 carbon atoms. "C_{1-10} alkyl" as used herein refers to an alkyl comprising 1 to 10 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl. The term (ar)alkyl or (heteroaryl)alkyl indicate the alkyl group is optionally substituted by an aryl or a heteroaryl group respectively.


The term "cycloalkyl" refers to an unsubstituted or substituted carbocycle, in which the carbocycle contains 3 to 10 carbon atoms; preferably 3 to 8 carbon atoms; more preferably 3 to 6 carbon atoms (i.e., lower cycloalkyls). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, 2-methyl-cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term "cycloalkyl alkyl" refers to an additionally unsubstituted or substituted alkyl substituted by a lower cycloalkyl. Examples of cycloalkyl alkyls include, but are not limited to, any one of methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl that is substituted with cyclopropyl, 2-methyl-cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Gilead Exhibit 2029
PGR2023-00046 - Page 002065

The term "cycloheteroalkyl" refers to an unsubstituted or substituted heterocycle, in which the heterocycle contains 2 to 9 carbon atoms; preferably 2 to 7 carbon atoms; more preferably 2 to 5 carbon atoms. Examples of cycloheteroalkyls include, but are not limited to, aziridin-2-yl, *N*-C_{1-3}-alkyl-aziridin-2-yl, azetidinyl, *N*-C_{1-3}-alkyl-azetidin-m'-yl, pyrrolidin-m'-yl, *N*-C_{1-3}-alkyl-pyrrolidin-m'-yl, piperidin-m'-yl, and *N*-C_{1-3}-alkyl-piperidin-m'-yl, where m' is 2, 3, or 4 depending on the cycloheteroalkyl. Specific examples of N-C_{1-3}-alkyl-cycloheteroalkyls include, but are not limited to, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-2-yl, N-methyl-piperidin-3-yl, and N-methyl-piperidin-4-yl. In the instance of R^4, the point of attachment between the cycloheteroalkyl ring carbon and the oxygen occurs at any one of m'

The term "heterocycle" refers to an unsubstituted or substituted heterocycle containing carbon, hydrogen, and at least one of N, O, and S, where the C and N can be trivalent or tetravalent, i.e., sp^2- or sp^3-hybridized. Examples of heterocycles include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, imidazole, oxazole, piperazine, etc. In the instance of piperazine, as related to R^{10} for NR'_2, the corresponding opposite nitrogen atom of the piperazinyl is substituted by a lower alkyl represented by the following structure:



Preferably, the opposite nitrogen of the piperazinyl is substituted by a methyl group.

The term "halogenated alkyl" (or "haloalkyl") refers to an unbranched or branched chain alkyl comprising at least one of F, Cl, Br, and I. The term "C_{1-M} haloalkyl" refers to an alkyl comprising 1 to M carbon atoms that comprises at least one of F, Cl, Br, and I, where M is an integer having the following values: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. "C_{1-3} haloalkyl" refers to a haloalkyl comprising 1 to 3 carbons and at least one of F, Cl, Br, and I. The term "halogenated lower alkyl" (or "lower haloalkyl") refers to a haloalkyl comprising 1 to 6

Gilead Exhibit 2029
PGR2023-00046 - Page 002066

carbon atoms and at least one of F, Cl, Br, and I. Examples include, but are not limited to, fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, dichloromethyl, dibromomethyl, diiodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-difluoroethyl, 2,2-dichloroethyl, 2,2-dibromomethyl, 2-2-diiodomethyl, 3-fluoropropyl, 3-chloropropyl, 3-bromopropyl, 2,2,2-trifluoroethyl or 1,1,2,2,2-pentafluoroethyl.

The term "alkynyl" refers to an unbranched or branched hydrocarbon chain radical having from 2 to 10 carbon atoms, preferably 2 to 5 carbon atoms, and having one triple bond. The term "$C_{2\text{-}N}$ alkynyl" refers to an alkynyl comprising 2 to N carbon atoms, where N is an integer having the following values: 3, 4, 5, 6, 7, 8, 9, or 10. The term "C $C_{2\text{-}4}$ alkynyl" refers to an alkynyl comprising 2 to 4 carbon atoms. The term "$C_{2\text{-}10}$ alkynyl" refers to an alkynyl comprising 2 to 10 carbons. Examples include, but are limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.

The term "halogenated alkynyl" refers to an unbranched or branched hydrocarbon chain radical having from 2 to 10 carbon atoms, preferably 2 to 5 carbon atoms, and having one triple bond and at least one of F, Cl, Br, and I.

The term "cycloalkyl" refers to a saturated carbocyclic ring comprising 3 to 8 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. The term "$C_{3\text{-}7}$ cycloalkyl" as used herein refers to a cycloalkyl comprising 3 to 7 carbons in the carbocyclic ring.

The term "alkoxy" refers to an -O-alkyl group or an –O-cycloalkyl group, wherein alkyl and cycloalkyl are as defined above. Examples of –O-alkyl groups include, but are not limited to, methoxy, ethoxy, *n*-propyloxy, *i*-propyloxy, *n*-butyloxy, *i*-butyloxy, *t*-butyloxy. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "$C_{1\text{-}10}$ alkoxy" refers to an-O-alkyl wherein alkyl is $C_{1\text{-}10}$. Examples of –O-cycloalkyl groups include, but are not limited to, -O-*c*-propyl, -O-*c*-butyl, -O-*c*-pentyl, and –O-*c*-hexyl.

Gilead Exhibit 2029
PGR2023-00046 - Page 002067

The term "halogenated alkoxy" refers to an –O-alkyl group in which the alkyl group comprises at least one of F, Cl, Br, and I.

The term "halogenated lower alkoxy" refers to an –O-(lower alkyl) group in which the lower alkyl group comprises at least one of F, Cl, Br, and I.

The term "amino acid" includes naturally occurring and synthetic α, β γ or δ amino acids, and includes but is not limited to, amino acids found in proteins, i.e. glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In a preferred embodiment, the amino acid is in the L-configuration. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, β-alanyl, β-valinyl, β-leucinyl, β-isoleucinyl, β-prolinyl, β-phenylalaninyl, β-tryptophanyl, β-methioninyl, β-glycinyl, β-serinyl, β-threoninyl, β-cysteinyl, β-tyrosinyl, β-asparaginyl, β-glutaminyl, β-aspartoyl, β-glutaroyl, β-lysinyl, β-argininyl or β-histidinyl. When the term amino acid is used, it is considered to be a specific and independent disclosure of each of the esters of α, β γ or δ glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine in the D and L-configurations.

The term "aminoacyl" includes N,N-unsubstituted, N,N-monosubstituted, and N,N-disubstituted derivatives of naturally occurring and synthetic α, β γ or δ amino acyls, where the amino acyls are derived from amino acids. The amino-nitrogen can be substituted or unsubstituted. When the amino-nitrogen is substituted, the nitrogen is either mono- or di-substituted, where the substituent bound to the amino-nitrogen is a lower alkyl or an alkaryl. In the instance of its use for Y, the expression "O(aminoacyl)" is used. It is understood that the C3' carbon of the ribose is bound to the oxygen "O", which is then bound to the carbonyl carbon of the aminoacyl.

Gilead Exhibit 2029
PGR2023-00046 - Page 002068

The terms "alkylamino" or "arylamino" refer to an amino group that has one or two alkyl or aryl substituents, respectively.

The term "protected," as used herein and unless otherwise defined, refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis. Non-limiting examples include: C(O)-alkyl, C(O)Ph, C(O)aryl, CH_3, CH_2-alkyl, CH_2-alkenyl, CH_2Ph, CH_2-aryl, CH_2O-alkyl, CH_2O-aryl, SO_2-alkyl, SO_2-aryl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, and 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).

The term "aryl," as used herein, and unless otherwise specified, refers to substituted or unsubstituted phenyl (Ph), biphenyl, or naphthyl, preferably the term aryl refers to substituted or unsubstituted phenyl. The aryl group can be substituted with one or more moieties selected from among hydroxyl, F, Cl, Br, I, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in T.W. Greene and P.G. M. Wuts, "Protective Groups in Organic Synthesis," 3rd ed., John Wiley & Sons, 1999.

The terms "alkaryl" or "alkylaryl" refer to an alkyl group with an aryl substituent, such as benzyl. The terms "aralkyl" or "arylalkyl" refer to an aryl group with an alkyl substituent.

The term "di(lower alkyl)amino-lower alkyl" refers to a lower alkyl substituted by an amino group that is itself substituted by two lower alkyl groups. Examples include, but are not limited to, $(CH_3)_2NCH_2$, $(CH_3)_2NCH_2CH_2$, $(CH_3)_2NCH_2CH_2CH_2$, etc. The examples above show lower alkyls substituted at the terminus carbon atom with an N,N-dimethyl-amino substituent. These are intended as examples only and are not intended to limit the meaning of the term "di(lower alkyl)amino-lower alkyl" so as to require the same. It is contemplated that the lower alkyl chain can be substituted with an N,N-di(lower alkyl)-amino at any point along the chain, e.g., CH_3CH(N-(lower alkyl)$_2$)CH_2CH_2.

Gilead Exhibit 2029
PGR2023-00046 - Page 002069

The term "halo," as used herein, includes chloro, bromo, iodo and fluoro.

The term "acyl" refers to a substituent containing a carbonyl moiety and a non-carbonyl moiety. The carbonyl moiety contains a double-bond between the carbonyl carbon and a heteroatom, where the heteroatom is selected from among O, N and S. When the heteroatom is N, the N is substituted by a lower alkyl. The non-carbonyl moiety is selected from straight, branched, and cyclic alkyl, which includes, but is not limited to, a straight, branched, or cyclic C_{1-20} alkyl, C_{1-10} alkyl, or lower alkyl; alkoxyalkyl, including methoxymethyl; aralkyl, including benzyl; aryloxyalkyl, such as phenoxymethyl; or aryl, including phenyl optionally substituted with halogen (F, Cl, Br, I), hydroxyl, C_1 to C_4 alkyl, or C_1 to C_4 alkoxy, sulfonate esters, such as alkyl or aralkyl sulphonyl, including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. When at least one aryl group is present in the non-carbonyl moiety, it is preferred that the aryl group comprises a phenyl group.

The term "lower acyl" refers to an acyl group in which the non-carbonyl moiety is lower alkyl.

The term "purine" or "pyrimidine" base includes, but is not limited to, adenine, N^6-alkylpurines, N^6-acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N^6-benzylpurine, N^6-halopurine, N^6-vinylpurine, N^6-acetylenic purine, N^6-acyl purine, N^6-hydroxyalkyl purine, N^6-allcylaminopurine, N^6-thioallcyl purine, N^2-alkylpurines, N^2-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-fluorouracil, C^5-alkylpyrimidines, C^5-benzylpyrimidines, C^5-halopyrimidines, C^5-vinylpyrimidine, C^5-acetylenic pyrimidine, C^5-acyl pyrimidine, C^5-hydroxyalkyl purine, C^5-amidopyrimidine, C^5-cyanopyrimidine, ,C^5-iodopyrimidine, C^6-lodo-pyrimidine, C^5-Br-vinyl pyrimidine, C^6-Br-vinyl pyrimidine, C^5-nitropyrimidine, C^5-amino-pyrimidine, N^2-alkylpurines, N^2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl. Purine bases include, but are not limited to, guanine, adenine,

Gilead Exhibit 2029
PGR2023-00046 - Page 002070


hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, and *t*-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.

The term "tautomerism" and "tautomers" have their accepted plain meanings.

The term "P*" means that the phosphorous atom is chiral and that it has a corresponding Cahn-Ingold-Prelog designation of "R" or "S" which have their accepted plain meanings. It is contemplated that compounds of the formula I are racemic because the chirality at phosphorous. Applicants contemplate use of the racemate and/or the resolved enantiomers. In some instances, an asterisk does not appear next to the phosphoroamidate phosphorous atom. In these instances, it is understood that the phosphorous atom is chiral and that one of ordinary skill understands this to be so unless the substituents bound to the phosphorous exclude the possibility of chirality at phosphorous, such as in $P(O)Cl_3$.

DETAILED DESCRIPTION OF THE INVENTION

An aspect of the invention is directed to a compound, its salts, hydrates, solvates, crystalline forms, and the like represented by formula I:



wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are

Gilead Exhibit 2029
PGR2023-00046 - Page 002071

optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1"}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1"}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3"}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3"}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or $-N(R^{3'})_2$);

Gilead Exhibit 2029
PGR2023-00046 - Page 002072

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Gilead Exhibit 2029
PGR2023-00046 - Page 002073



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6,

Gilead Exhibit 2029
PGR2023-00046 - Page 002074

halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

As can be appreciated from the structure represented by formula **I** above, there are myriad ways to express the several embodiments and aspects of each embodiment of the present invention. As seen below, the inventors have disclosed certain embodiments directed to the compound of formula **I**, each having several aspects, based on the identity of the modified purine or pyrimidine base. This is not intended to be an explicit or implicit admission that the three embodiments are independent or distinct nor should it be interpreted as such. Rather, it is intended to convey information so that the full breadth of the present invention can be understood. Furthermore, the following embodiments, and aspects thereof, are not meant to be limiting on the full breadth of the invention as recited by the structure of formula **I**.

A first embodiment of the invention is directed to a compound represented by formula **I-1**:



I-1

Gilead Exhibit 2029
PGR2023-00046 - Page 002075

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-

Gilead Exhibit 2029
PGR2023-00046 - Page 002076

Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)-amino, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$

Gilead Exhibit 2029
PGR2023-00046 - Page 002077

alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^7, R^8,R^9 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

A first aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

(a) R^1 is hydrogen, n-alkyl or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), or CH_2SH and R^{3b} is H;

Gilead Exhibit 2029
PGR2023-00046 - Page 002078

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, vinyl, OCH_3, OCH_2CH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, vinyl, N_3, CN, Cl, Br, F, I, O(C_{1-6} acyl), O(C_{1-4} alkyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-4} haloalkyl, O(aminoacyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, or N(C_{1-4} acyl)$_2$;

(i) R^7, R^8,R^9 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

A second aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002079

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a C_{1-3} alkyl, a C_{1-3} alkoxy, F, Cl, Br, I, nitro, cyano, and a C_{1-3} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), or CH_2SH and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

Gilead Exhibit 2029
PGR2023-00046 - Page 002080

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A third aspect of the first embodiment is directed to a compound represented by formula **I-1**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'\text{-}OH)\text{-}Ph)$, CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'\text{-}OH)\text{-}Ph)$, CH_2SH, or lower cycloalkyl and R^{3b} is H;

Gilead Exhibit 2029
PGR2023-00046 - Page 002081

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;


(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl'; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A fourth aspect of the first embodiment is directed to a compound represented by formula **I-2**

Gilead Exhibit 2029
PGR2023-00046 - Page 002082



I-2

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

Gilead Exhibit 2029
PGR2023-00046 - Page 002083

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH , base is cytosine and R^6 is H, R^5 cannot be N_3;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, OC(O)(C1-20 alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, NHC(O)(C1-20 alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and and $N(C(O)(CH_2)_sCH_3$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A fifth aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002084

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, di(lower alkyl)amino-lower alkyl, or aminoacyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A sixth aspect of the first embodiment is directed to a compound represented by formula **I-2**

Gilead Exhibit 2029
PGR2023-00046 - Page 002085

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkyl optionally substituted with a lower alkyl, alkoxy or halogen, $C_{1\text{-}10}$ haloalkyl, $C_{3\text{-}10}$ cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, OMe, CN, CH_2F, F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, or N_3, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3\text{-}q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1\text{-}20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1\text{-}20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A seventh aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002086

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;

(h) Y is OH, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$; and

(j) R^9 is selected from among OH, OCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from among 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

An eighth aspect of the first embodiment is directed to a compound represented by formula **I-2**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002087

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;

(h) Y is OH, OCH_3, $OC(O)CH_3$, or O(aminoacyl);

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$;


(j) R^9 is selected from among OH, OCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, $OC(O)(C_{1-20}$ alkyl), which include but are not limited to $OC(O)(CH_2)_sCH_3$, $NHC(O)(C_{1-20}$ alkyl), which include but are not limited to $NHC(O)(CH_2)_sCH_3$, and $N(C(O)(CH_2)_sCH_3)_2$, which include but is not limited to $N(C(O)(CH_2)_sCH_3)_2$, where s is an integer selected from among 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

A second embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **b** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, Y, R^7, and $R^8$are defined in the Summary of the Invention section above.

A first aspect of the second embodiment is directed to a compound represented by

Gilead Exhibit 2029
PGR2023-00046 - Page 002088

formula **I-3**



I-3

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are

Gilead Exhibit 2029
PGR2023-00046 - Page 002089

$(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl),

Gilead Exhibit 2029
PGR2023-00046 - Page 002090

$S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, or $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, or $N(C_{1-4}$ acyl)$_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The second aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi)

Gilead Exhibit 2029
PGR2023-00046 - Page 002091

R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), or CH_2SH and R^{3b} is H;

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, CN, CH_3, vinyl, OCH_3, OCH_2CH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, vinyl, N_3, CN, Cl, Br, F, I, O(C_{1-6} acyl), O(C_{1-4} alkyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-18} acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, OC(O)O(C_{1-4} alkyl), OC(O)O(C_{1-4} alkyl), OC(O)O(C_{2-4} alkynyl), OC(O)O(C_{2-4} alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{2-4} alkenyl), S(C_{1-4} acyl), S(C_{1-4} alkyl), S(C_{2-4} alkynyl), S(C_{2-4} alkenyl), SO(C_{1-4} acyl), SO(C_{1-4} alkyl), SO(C_{2-4} alkynyl), SO(C_{2-4} alkenyl), SO_2(C_{1-4} acyl), SO_2(C_{1-4} alkyl), SO_2(C_{2-4} alkynyl), SO_2(C_{2-4} alkenyl), $OS(O)_2$(C_{1-4} acyl), $OS(O)_2$(C_{1-4} alkyl), $OS(O)_2$(C_{2-4} alkenyl), NH_2, NH(C_{1-4} alkyl), NH(C_{2-4} alkenyl), NH(C_{2-4} alkynyl), NH(C_{1-4} acyl), N(C_{1-4} alkyl)$_2$, N(C_{1-4} acyl)$_2$;

Gilead Exhibit 2029
PGR2023-00046 - Page 002092

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl, halogenated (F, Cl, Br, I) lower alkyl, lower alkenyl of C_2-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The third aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a C_{1-3} alkyl, a C_{1-3} alkoxy, F, Cl, Br, I, nitro, cyano, and a C_{1-3} haloalkyl;

(b) R^2 is hydrogen, CH_3, R^{3a} or R^{3b} and R^2 together are $(CH_2)_3$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b} are as defined herein;

(c) R^{3a} and R^{3b} are independently (i) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 3 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Gilead Exhibit 2029
PGR2023-00046 - Page 002093

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

The fourth aspect of the second embodiment is directed to a compound represented by formula **I-3**

wherein

(a) R^1 is hydrogen, n-alkyl or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -

Gilead Exhibit 2029
PGR2023-00046 - Page 002094

$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2(halo), such as CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The fifth aspect of the second embodiment is directed to a compound represented by formula **I-4**

Gilead Exhibit 2029
PGR2023-00046 - Page 002095



I-4

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002096

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl,

The sixth aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'\text{-}OH)\text{-}Ph)$, CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002097

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^7 and R^8 are independently H, F, Cl, Br, I, OH, OCH_3, SH, SCH_3, NH_2, $NHCH_3$, $N(CH_3)_2$, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2H, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$, wherein R' is a C_{1-20} alkyl; a C_{1-20} cycloalkyl; a C_2-C_6 alkenyl, a C_2-C_6 alkynyl.

The seventh aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{t}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, OMe, CN, CH_2F, F, Cl, Br, or I;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

Gilead Exhibit 2029
PGR2023-00046 - Page 002098

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$;

The eighth aspect of the second embodiment is directed to a compound represented by formula **I-4**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

The ninth aspect of the second embodiment is directed to a compound represented by formula **I-4**

Gilead Exhibit 2029
PGR2023-00046 - Page 002099

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, or N_3;


(h) Y is OH, OCH_3, or $OC(O)CH_3$;

(i) R^7 and R^8 are independently H, F, Br, SCH_3, CH_3, $CH_{3-q}X_q$, where X is F, Cl, Br, or I and q is 1 to 3, vinyl, CO_2CH_3, $CONH_2$, $CONHCH_3$, or $CON(CH_3)_2$.

A third embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **c** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, Y, Z, R^{10}, R^{11}, and R^{12} are defined in the Summary of the Invention section above; with the proviso that R^{11} is not H.

A first aspect of the third embodiment is directed to a compound represented by formula **I-5**

Gilead Exhibit 2029
PGR2023-00046 - Page 002100



I-5

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1"}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1"}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3"}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Gilead Exhibit 2029
PGR2023-00046 - Page 002101

or C_{1-6} alkyl and $R^{3"}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is from H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

Gilead Exhibit 2029
PGR2023-00046 - Page 002102

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} and R^{11} are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, $C(O)(C_{1-20}$ alkyl), $C(O)(C_{1-10}$ alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F,

Gilead Exhibit 2029
PGR2023-00046 - Page 002103

Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A second aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, $CH_2((4'\text{-}OH)\text{-}Ph)$, CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

Gilead Exhibit 2029
PGR2023-00046 - Page 002104

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A third aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

Gilead Exhibit 2029
PGR2023-00046 - Page 002105

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fourth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

Gilead Exhibit 2029
PGR2023-00046 - Page 002106

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fifth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002107

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A sixth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002108

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A seventh aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

Gilead Exhibit 2029
PGR2023-00046 - Page 002109

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$.

An eighth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002110

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A ninth aspect of the third embodiment is directed to a compound represented by formula **I-5**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002111

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, or N-methyl-pyrrolidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R';


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A tenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

Gilead Exhibit 2029
PGR2023-00046 - Page 002112



I-6

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1"}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1"}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3"}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Gilead Exhibit 2029
PGR2023-00046 - Page 002113

or C_{1-6} alkyl and $R^{3"}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

Gilead Exhibit 2029
PGR2023-00046 - Page 002114

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

An eleventh aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH,

Gilead Exhibit 2029
PGR2023-00046 - Page 002115

$CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A twelvth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002116

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R', with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is a H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A thirteenth aspect of the third embodiment is directed to a compound represented

Gilead Exhibit 2029
PGR2023-00046 - Page 002117

by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

Gilead Exhibit 2029
PGR2023-00046 - Page 002118

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fourteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$, with the proviso that when R^{10} is OH and R^{11} is not NH_2;

Gilead Exhibit 2029
PGR2023-00046 - Page 002119

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A fifteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Gilead Exhibit 2029
PGR2023-00046 - Page 002120

or C_{1-6} alkyl and $R^{3"}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl),

Gilead Exhibit 2029
PGR2023-00046 - Page 002121

$SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2$R'.

An sixteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH,

Gilead Exhibit 2029
PGR2023-00046 - Page 002122

$CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

A seventeenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002123

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$;

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$.

An eighteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002124

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO_2H, or CH=CHCO_2R'.

A nineteenth aspect of the third embodiment is directed to a compound represented by formula **I-6**

Gilead Exhibit 2029
PGR2023-00046 - Page 002125

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is NH_2 and R^{11} are independently H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R';

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and


(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

Gilead Exhibit 2029
PGR2023-00046 - Page 002126

A fourth embodiment of the invention is directed to a compound represented by formula I in which the base is a structure represented by formula **c** above, where R^{11} is H and R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y are defined in the Summary of the Invention section above.

A first aspect of the fourth embodiment is directed to a compound represented by formula **I-7**



I-7

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, -

Gilead Exhibit 2029
PGR2023-00046 - Page 002127

$(CH_2)_eCOR^{3"}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3"}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Gilead Exhibit 2029
PGR2023-00046 - Page 002128

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

(i) R^{10} is H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, $C(O)(C_{1-20}$ alkyl), $C(O)(C_{1-10}$ alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

Gilead Exhibit 2029
PGR2023-00046 - Page 002129

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'$_2$, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that R^{12} is not a: (i) –C≡C–H, (ii) –$C{=}CH_2$, or (iii) $–NO_2$.

A second aspect of the fourth embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Gilead Exhibit 2029
PGR2023-00046 - Page 002130

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A third aspect of the third embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002131

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A fourth aspect of the fourth embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Gilead Exhibit 2029
PGR2023-00046 - Page 002132

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} and R^{11} H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A fifth aspect of the fourth embodiment is directed to a compound represented by formula **I-7**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002133

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R',


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, or CH=CHCO$_2$R'.

A sixth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

Gilead Exhibit 2029
PGR2023-00046 - Page 002134



I-8

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Gilead Exhibit 2029
PGR2023-00046 - Page 002135

or C_{1-6} alkyl and $R^{3"}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl),

Gilead Exhibit 2029
PGR2023-00046 - Page 002136

$OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl$)_2$, $N(C_{1-18}$ acyl$)_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl$)_2$, $N(C_{1-4}$ acyl$)_2$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

A seventh aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

Gilead Exhibit 2029
PGR2023-00046 - Page 002137

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2$R',

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2$R'; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

An eighth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002138

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl , N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'$_2$, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A ninth aspect of the fourth embodiment is directed to a compound represented by

Gilead Exhibit 2029
PGR2023-00046 - Page 002139

formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'$_2$, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$,

wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

Gilead Exhibit 2029
PGR2023-00046 - Page 002140

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A tenth aspect of the fourth embodiment is directed to a compound represented by formula **I-8**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

(i) R^{10} is H, F, Br, I, OH, OR', NH_2, NHR', NR'_2, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

Gilead Exhibit 2029
PGR2023-00046 - Page 002141


wherein R' is a lower alkyl, a lower cycloalkyl, or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

(j) Z is N or CR^{12}; and

R^{12} is an H, halogen (including F, Cl, Br, I), OR', NH_2, NHR', NR'_2, NO_2, lower alkyl of C_1-C_6, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

A fifth embodiment of the invention is directed to a compound represented by formula **I** in which the base is a structure represented by formula **d** above, wherein R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y are defined in the Summary of the Invention section above.

The first aspect of the fifth embodiment is directed to a compound represented by formula **I-9**



I-9

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$

Gilead Exhibit 2029
PGR2023-00046 - Page 002142

alkyl, $-SO_2N(R^{1'})_2$, $COR^{1"}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1"}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3"}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3"}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3"}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, di(lower alkyl)amino-lower alkyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002143

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$.

A second aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002144

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H.

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, halogen, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3;

A third aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Gilead Exhibit 2029
PGR2023-00046 - Page 002145

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I; with the proviso that X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 N_3, OCH_3, or $OC(O)CH_3$;

A fourth aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

Gilead Exhibit 2029
PGR2023-00046 - Page 002146

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A fifth aspect of the fifth embodiment is directed to a compound represented by formula **I-9**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A sixth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

Gilead Exhibit 2029
PGR2023-00046 - Page 002147



I-10

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, or a substituted or unsubstituted phenyl, where the substitutent of the substituted phenyl is at least one of a CH_3, OCH_3, F, Cl, Br, I, nitro, cyano, and a $CH_{3-q}X_q$, where X is F, Cl, Br, or I, and q is 1-3;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl or R^{3a} is CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

Gilead Exhibit 2029
PGR2023-00046 - Page 002148

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, N_3, CH_2CN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3;

(h) Y is OH, H, CH_3, vinyl, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3, NH_2, $NHCH_3$, NH(vinyl), NH(acetyl), $NH(C(O)CH_3)$, $N(CH_3)_2$, $N(C(O)CH_3)_2$;

A seventh aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_3, OCH_3, CH_2OH, CH_2F, halogen, including F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Gilead Exhibit 2029
PGR2023-00046 - Page 002149

(g) X is H, OH, F, OCH_3, Cl, Br, I, NH_2, or N_3; and

(h) Y is OH, H, CH_3, vinyl, NH_2, N_3, CN, Cl, Br, F, I, $OC(O)CH_3$, OCH_3.

An eighth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen or CH_3;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, CN, CH_2F, F, Cl, Br, or I, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, F, OCH_3, F, Cl, Br, I, NH_2 or N_3;

(h) Y is H, OH, CH_3, F, Cl, Br, I, NH_2 or N_3, OCH_3, or $OC(O)CH_3$;

A ninth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

Gilead Exhibit 2029
PGR2023-00046 - Page 002150

(a) R^1 is hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, phenyl, p-tolyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;

(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$;

A tenth aspect of the fifth embodiment is directed to a compound represented by formula **I-10**

wherein

(a) R^1 is hydrogen, methyl, phenyl, p-bromo-phenyl, p-chloro-phenyl, p-fluorophenyl;

(b) R^2 is hydrogen;

(c) R^{3a} is H and R^{3b} is H, CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, or lower cycloalkyl;

(d) R^4 is hydrogen, CH_3, Et, ^{i}Pr, ^{n}Pr, ^{n}Bu, 2-butyl, ^{t}Bu, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N-methyl-aziridin-2-yl, N-methyl-azetidin-3-yl, N-

Gilead Exhibit 2029
PGR2023-00046 - Page 002151

methyl-pyrrolidin-3-yl, N-methyl-pyrrolidin-4-yl, N-methyl-piperidin-4-yl, lower haloalkyl, or di(lower alkyl)amino-lower alkyl;

(e) R^5 is H, with the provisos that when X is OH, R^6 is CH_3 or CH_2F, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, or F;


(g) X is H, OH, OCH_3, F, NH_2 or N_3;

(h) Y is OH, NH_2, OCH_3, or $OC(O)CH_3$.

The following tables contain numeric identifiers associated with various substituent designators that should be viewed in light of the accompanying structure. These structures are contemplated species of the various aspects of the disclosed embodiments and are not intended to be limiting on full breadth of the contemplated compound represented by the structure of formula **I**. However, it is contemplated that any one of the exemplified nucleoside bases can be used in combination with any one of contemplated species that specify a particular combination of R^1, R^2, R^{3a}, R^{3b}, R^4, R^5, R^6, X, and Y. In each of the presented tables, the phosphoramidate substituent containing the substituents R^{3a} and R^{3b} are depicted without reference to stereochemical structure (*cf.* structures **I-1**, **I-3**, **I-5**, **I-7**, and **I-9** above). It is contemplated that the compounds recited below embody compounds in which R^{3a} projects toward the viewer while R^{3b} projects away from the viewer (cf. structures **I-2**, **I-4**, **I-6**, **I-8**, and **I-10**). Moreover, it is contemplated that the compounds recited below also embody compounds in which R^{3a} projects away from the viewer while R^{3b} projects towards the viewer. Not meant to be limiting, however, it is contemplated that preferred compounds are those in which R^{3a} projects towards the viewer and R^{3b} projects away from the viewer such that the natural L-amino acid (S)-configuration is presented. Additionally, the inventors recognize that the phosphorus atom of the phosphoramidate moiety is another source of chirality. Although the structures below do not specifically depict chirality at phosphorus, the inventors recognize that stereochemical configurations are possible such that in a staggered (or zig-zag) line structure the oxo-substitutent projects towards the viewer

Gilead Exhibit 2029
PGR2023-00046 - Page 002152

while the OR^1 substitutent projects away from the viewer, and vice versa, i.e., where the Cahn-Ingold-Prelog stereochemical designation of phosphorous is either R or S. Therefore, the structures below include all possible stereochemical configurations possible for phosphorus.



II

Table II-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-1-1	CH_3	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-1-8	CH_3	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-2-1	Et	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-2	Et	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002153

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-2-8	Et	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-5-1	Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002154

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-5-8	Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Gilead Exhibit 2029
PGR2023-00046 - Page 002155

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	OH	OH	H	H	NH_2
II-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002156

Table II-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-11-1	CH_3	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-2	CH_3	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-11-8	CH_3	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-12-1	Et	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-2	Et	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-12-8	Et	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-13-1	^{i}Pr	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-13-8	^{i}Pr	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002157

Table II-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-14-1	^{t}Bu	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-14-8	^{t}Bu	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-15-1	Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-2	Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-15-8	Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002158

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-17-1	p-F-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-17-8	p-F-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002159

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-20-1	p-I-Ph	H	H	H	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	OH	OH	H	H	NH_2
II-20-8	p-I-Ph	*	H	*	Et	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-22-1	Et	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002160

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-22-8	Et	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002161

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002162

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2
II-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-31.

Gilead Exhibit 2029
PGR2023-00046 - Page 002163

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-32-1	Et	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-32-8	Et	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002164

Table II-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002165

Table II-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002166

Table II-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2
II-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-41-1	CH_3	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-41-8	CH_3	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-42-1	Et	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-2	Et	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-42-8	Et	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002167

Table II-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-45-1	Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-2	Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-45-8	Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002168

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002169

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table II-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
II-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	OH	OH	H	H	NH_2
II-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	OH	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002170



III

Table III-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-1-1	CH_3	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-2	CH_3	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-5	CH_3	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-1-8	CH_3	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-2-1	Et	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-2	Et	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-5	Et	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-2-8	Et	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002171

Table III-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-3-1	^{i}Pr	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-2	^{i}Pr	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-3-8	^{i}Pr	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-5-1	Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-2	Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-5	Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-5-8	Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002172

Table III-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-6-1	p-Me-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-6-8	p-Me-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-7-1	p-F-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-2	p-F-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-7-20	p-F-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-8-1	p-Cl-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-8-8	p-Cl-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002173

Table III-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-9-1	p-Br-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-9-20	p-Br-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-10-1	p-I-Ph	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-2	p-I-Ph	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
III-10-8	p-I-Ph	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-11-1	CH_3	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-11-2	CH_3	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-5	CH_3	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-11-8	CH_3	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002174

Table III-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-12-1	Et	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-12-2	Et	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-5	Et	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-12-8	Et	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-13-1	^{i}Pr	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-13-2	^{i}Pr	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-13-8	^{i}Pr	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-14-1	^{t}Bu	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-14-2	^{t}Bu	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002175

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-14-8	^{t}Bu	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-15-1	Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-15-2	Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-5	Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-15-8	Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-16-1	p-Me-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-16-2	p-Me-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-16-8	p-Me-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002176

Table III-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-17-1	p-F-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-17-2	p-F-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-17-8	p-F-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-18-1	p-Cl-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-18-2	p-Cl-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-18-8	p-Cl-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-19-1	p-Br-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-19-2	p-Br-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-19-8	p-Br-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002177

Table III-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-20-1	p-I-Ph	H	H	H	Et	H	CH_3	F	OH	H	H	NH_2
III-20-2	p-I-Ph	H	H	CH_3	Et	H	CH_3	F	OH	H	H	NH_2
III-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	CH_3	F	OH	H	H	NH_2
III-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	CH_3	F	OH	H	H	NH_2
III-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	CH_3	F	OH	H	H	NH_2
III-20-8	p-I-Ph	*	H	*	Et	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-21-1	CH_3	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-2	CH_3	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-21-8	CH_3	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-22-1	Et	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-2	Et	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-22-8	Et	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002178

Table III-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-23-1	^{i}Pr	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-23-8	^{i}Pr	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-24-1	^{t}Bu	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-24-8	^{t}Bu	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-25-1	Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-2	Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-25-8	Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002179

Table III-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-27-1	p-F-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-27-8	p-F-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002180

Table III-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-30-1	p-I-Ph	H	H	H	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	CH_3	F	OH	H	H	NH_2
III-30-8	p-I-Ph	*	H	*	^{i}Pr	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-31-1	CH_3	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-2	CH_3	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-31-8	CH_3	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002181

Table III-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-32-1	Et	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-2	Et	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-32-8	Et	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-33-1	^{i}Pr	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-33-8	^{i}Pr	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-34-1	^{t}Bu	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-34-8	^{t}Bu	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002182

Table III-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-35-1	Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-2	Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-35-8	Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-37-1	p-F-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-37-8	p-F-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002183

Table III-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-40-1	p-I-Ph	H	H	H	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	CH_3	F	OH	H	H	NH_2
III-40-8	p-I-Ph	*	H	*	^{n}Bu	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002184

Table III-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-41-1	CH_3	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-2	CH_3	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-5	CH_3	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-41-8	CH_3	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-42-1	Et	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-2	Et	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-5	Et	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-42-8	Et	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-43-1	^{i}Pr	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-2	^{i}Pr	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-43-8	^{i}Pr	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002185

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-44-1	^{t}Bu	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-2	^{t}Bu	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-44-8	^{t}Bu	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-45-1	Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-2	Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-5	Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-45-8	Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-46-1	p-Me-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-2	p-Me-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002186

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-46-8	p-Me-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-47-1	p-F-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-2	p-F-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-47-8	p-F-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-48-1	p-Cl-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-48-8	p-Cl-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-49-1	p-Br-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-2	p-Br-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002187


№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-49-8	p-Br-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table III-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
III-50-1	p-I-Ph	H	H	H	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-2	p-I-Ph	H	H	CH_3	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	CH_3	F	OH	H	H	NH_2
III-50-8	p-I-Ph	*	H	*	Bz	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



IV

Table IV-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-1-1	CH_3	H	H	H	CH_3	H	F	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002188

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-1-2	CH_3	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-1-8	CH_3	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-2-1	Et	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-2-2	Et	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-5	Et	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-2-8	Et	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-3-1	^{i}Pr	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-3-8	^{i}Pr	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-4.

Gilead Exhibit 2029
PGR2023-00046 - Page 002189

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-4-1	^{t}Bu	H	H	H	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-2	^{t}Bu	H	H	CH_3	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	CH_3	F	OH	H	H	NH_2
IV-4-8	^{t}Bu	*	H	*	CH_3	H	CH_3	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-5-1	Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-5-2	Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-5-8	Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-6-1	p-Me-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-6-8	p-Me-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002190

Table IV-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-7-1	p-F-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-7-20	p-F-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-9-1	p-Br-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-9-20	p-Br-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002191

Table IV-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-10-1	p-I-Ph	H	H	H	CH_3	H	F	F	OH	H	H	NH_2
IV-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	F	OH	H	H	NH_2
IV-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	F	OH	H	H	NH_2
IV-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	F	OH	H	H	NH_2
IV-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	F	OH	H	H	NH_2
IV-10-8	p-I-Ph	*	H	*	CH_3	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-11-1	CH_3	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-11-2	CH_3	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-11-5	CH_3	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-11-8	CH_3	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-12-1	Et	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-12-2	Et	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-12-5	Et	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-12-8	Et	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002192

Table IV-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-13-1	^{i}Pr	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-13-2	^{i}Pr	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-13-8	^{i}Pr	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-14-1	^{t}Bu	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-14-2	^{t}Bu	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-14-8	^{t}Bu	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Gilead Exhibit 2029
PGR2023-00046 - Page 002193

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-15-1	Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-15-2	Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-15-5	Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-15-8	Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-17-2	p-F-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002194

Table IV-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH	H	H	NH_2
IV-20-2	p-I-Ph	H	H	CH_3	Et	H	F	F	OH	H	H	NH_2
IV-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	F	OH	H	H	NH_2
IV-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	F	OH	H	H	NH_2
IV-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	F	OH	H	H	NH_2
IV-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	F	OH	H	H	NH_2
IV-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002195

Table IV-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-21-1	CH_3	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-21-8	CH_3	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-22-1	Et	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-2	Et	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-22-8	Et	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002196

Table IV-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-25-1	Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-25-8	Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002197

Table IV-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002198

Table IV-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-30-1	p-I-Ph	H	H	H	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	F	OH	H	H	NH_2
IV-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-31-1	CH_3	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-31-8	CH_3	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-32-1	Et	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-2	Et	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-32-8	Et	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002199

Table IV-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-35-1	Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-35-8	Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002200

Table IV-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002201

Table IV-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	F	OH	H	H	NH_2
IV-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-41-1	CH_3	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-41-2	CH_3	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-41-8	CH_3	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002202

Table IV-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-42-1	Et	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-42-2	Et	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-42-5	Et	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-42-8	Et	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-43-1	^{i}Pr	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-43-8	^{i}Pr	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-44-1	^{t}Bu	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-44-8	^{t}Bu	*	H	*	Bz	H	F	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002203

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-45-1	Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-45-2	Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-45-5	Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-45-8	Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002204

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table IV-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2
IV-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.


Table IV-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH	H	H	NH_2
IV-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	F	OH	H	H	NH_2
IV-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	F	OH	H	H	NH_2
IV-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002205

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
IV-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	F	OH	H	H	NH_2
IV-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	F	OH	H	H	NH_2
IV-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



V

Table V-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-1-1	CH_3	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-1-2	CH_3	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-1-5	CH_3	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-1-8	CH_3	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-2-1	Et	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-2-2	Et	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002206

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-2-5	Et	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-2-8	Et	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-3-1	^{i}Pr	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-3-2	^{i}Pr	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-3-8	^{i}Pr	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-4-1	^{t}Bu	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-4-2	^{t}Bu	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-4-8	^{t}Bu	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9

Gilead Exhibit 2029
PGR2023-00046 - Page 002207

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-5-1	Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-5-2	Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-5-5	Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-5-8	Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-6-1	p-Me-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-6-8	p-Me-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-7-1	p-F-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-7-2	p-F-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-7-20	p-F-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002208

Table V-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-8-1	p-Cl-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-8-8	p-Cl-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-9-1	p-Br-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-9-20	p-Br-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-10-1	p-I-Ph	H	H	H	CH_3	H	H	F	OH	H	H	NH_2
V-10-2	p-I-Ph	H	H	CH_3	CH_3	H	H	F	OH	H	H	NH_2
V-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	H	F	OH	H	H	NH_2
V-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	H	F	OH	H	H	NH_2
V-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	H	F	OH	H	H	NH_2
V-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	H	F	OH	H	H	NH_2
V-10-8	p-I-Ph	*	H	*	CH_3	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002209

Table V-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-11-1	CH_3	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-11-2	CH_3	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-11-5	CH_3	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-11-8	CH_3	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-12-1	Et	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-12-2	Et	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-12-5	Et	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-12-8	Et	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-13-1	^{i}Pr	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-13-2	^{i}Pr	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-13-8	^{i}Pr	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002210

Table V-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-14-1	^{t}Bu	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-14-2	^{t}Bu	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-14-8	^{t}Bu	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-15-1	Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-15-2	Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-15-5	Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-15-8	Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-16-2	p-Me-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002211

Table V-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-17-2	p-F-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-18-2	p-Cl-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-19-2	p-Br-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002212

Table V-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH	H	H	NH_2
V-20-2	p-I-Ph	H	H	CH_3	Et	H	H	F	OH	H	H	NH_2
V-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	H	F	OH	H	H	NH_2
V-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	H	F	OH	H	H	NH_2
V-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	H	F	OH	H	H	NH_2
V-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	H	F	OH	H	H	NH_2
V-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-21-1	CH_3	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-2	CH_3	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-21-8	CH_3	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-22-1	Et	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-2	Et	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-22-8	Et	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002213

Table V-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-23-1	^{i}Pr	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-23-8	^{i}Pr	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-24-1	^{t}Bu	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-24-8	^{t}Bu	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-25-1	Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-2	Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-25-8	Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002214

Table V-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-27-1	p-F-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-27-8	p-F-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002215

Table V-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-29-1	p-Br-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-30-1	p-I-Ph	H	H	H	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	H	F	OH	H	H	NH_2
V-30-8	p-I-Ph	*	H	*	^{i}Pr	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-31-1	CH_3	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-2	CH_3	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-31-8	CH_3	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002216

Table V-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-32-1	Et	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-2	Et	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-32-8	Et	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-33-1	^{i}Pr	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-33-8	^{i}Pr	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-34-1	^{t}Bu	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-34-8	^{t}Bu	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002217

Table V-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-35-1	Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-2	Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-35-8	Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-37-1	p-F-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-37-8	p-F-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002218

Table V-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-40-1	p-I-Ph	H	H	H	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	H	F	OH	H	H	NH_2
V-40-8	p-I-Ph	*	H	*	^{n}Bu	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002219

Table V-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-41-1	CH_3	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-41-2	CH_3	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-41-5	CH_3	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-41-8	CH_3	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-42-1	Et	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-42-2	Et	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-42-5	Et	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-42-8	Et	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-43-1	^{i}Pr	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-43-2	^{i}Pr	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-43-8	^{i}Pr	*	H	*	Bz	H	H	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002220

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-44-1	^{t}Bu	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-44-2	^{t}Bu	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-44-8	^{t}Bu	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-45-1	Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-45-2	Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-45-5	Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-45-8	Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-46-2	p-Me-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002221

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-47-2	p-F-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-49-2	p-Br-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002222


№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table V-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
V-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH	H	H	NH_2
V-50-2	p-I-Ph	H	H	CH_3	Bz	H	H	F	OH	H	H	NH_2
V-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	H	F	OH	H	H	NH_2
V-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	H	F	OH	H	H	NH_2
V-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	H	F	OH	H	H	NH_2
V-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	H	F	OH	H	H	NH_2
V-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.



VI

Gilead Exhibit 2029
PGR2023-00046 - Page 002223

Table VI-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-1-1	CH_3	H	H	H	CH_3	H	F	H	OH	H	H
VI-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-1-8	CH_3	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-2-1	Et	H	H	H	CH_3	H	F	H	OH	H	H
VI-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-2-8	Et	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH	H	H
VI-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002224

Table VI-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH	H	H
VI-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-5-1	Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-5-8	Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002225

Table VI-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH	H	H
VI-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002226

Table VI-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-10-1	p-I-Ph	H	H	**H**	CH_3	H	F	H	OH	H	H
VI-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H
VI-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H
VI-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H
VI-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H
VI-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H
VI-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-11-1	CH_3	H	H	**H**	Et	H	F	H	OH	H	H
VI-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH	H	H
VI-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-11-8	CH_3	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-12-1	Et	H	H	H	Et	H	F	H	OH	H	H
VI-12-2	Et	H	H	CH_3	Et	H	F	H	OH	H	H
VI-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-12-8	Et	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002227

Table VI-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH	H	H
VI-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH	H	H
VI-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH	H	H
VI-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH	H	H
VI-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-15-1	Ph	H	H	H	Et	H	F	H	OH	H	H
VI-15-2	Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-15-8	Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002228

Table VI-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002229

Table VI-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH	H	H
VI-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH	H	H
VI-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H
VI-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H
VI-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H
VI-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H
VI-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002230

Table VI-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002231

Table VI-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H
VI-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002232

Table VI-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-28-1	p-Cl-Ph	H	H	**H**	^{i}Pr	H	F	H	OH	H	H
VI-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-29.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-29-1	p-Br-Ph	H	H	**H**	^{i}Pr	H	F	H	OH	H	H
VI-29-2	p-Br-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-29-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-29-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-29-5	p-Br-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-29-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-29-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-29-8	p-Br-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-30.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-30-1	p-I-Ph	H	H	**H**	^{i}Pr	H	F	H	OH	H	H
VI-30-2	p-I-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H
VI-30-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-30-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H
VI-30-5	p-I-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H
VI-30-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H
VI-30-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H
VI-30-8	p-I-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002233

Table VI-31.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-31-1	CH_3	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-31-2	CH_3	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-31-3	CH_3	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-31-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-31-5	CH_3	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-31-6	CH_3	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-31-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-31-8	CH_3	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-32.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-32-1	Et	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-32-2	Et	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-32-3	Et	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-32-4	Et	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-32-5	Et	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-32-6	Et	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-32-7	Et	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-32-8	Et	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-33.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-33-1	^{i}Pr	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-33-2	^{i}Pr	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-33-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-33-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-33-5	^{i}Pr	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-33-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-33-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-33-8	^{i}Pr	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002234

Table VI-34.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-34-1	^{t}Bu	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-34-2	^{t}Bu	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-34-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-34-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-34-5	^{t}Bu	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-34-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-34-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-34-8	^{t}Bu	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-35.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-35-1	Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-35-2	Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-35-3	Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-35-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-35-5	Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-35-6	Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-35-7	Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-35-8	Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-36.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-36-1	p-Me-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-36-2	p-Me-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-36-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-36-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-36-5	p-Me-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-36-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-36-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-36-8	p-Me-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002235

Table VI-37.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-37-1	p-F-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-37-2	p-F-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-37-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-37-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-37-5	p-F-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-37-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-37-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-37-8	p-F-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-38.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-38-1	p-Cl-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-38-2	p-Cl-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-38-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-38-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-38-5	p-Cl-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-38-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-38-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-38-8	p-Cl-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-39.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-39-1	p-Br-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-39-2	p-Br-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-39-3	p-Br-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-39-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-39-5	p-Br-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-39-6	p-Br-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-39-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-39-8	p-Br-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002236

Table VI-40.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-40-1	p-I-Ph	H	H	H	^{n}Bu	H	F	H	OH	H	H
VI-40-2	p-I-Ph	H	H	CH_3	^{n}Bu	H	F	H	OH	H	H
VI-40-3	p-I-Ph	H	H	$CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-40-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	^{n}Bu	H	F	H	OH	H	H
VI-40-5	p-I-Ph	H	H	CH_2Ph	^{n}Bu	H	F	H	OH	H	H
VI-40-6	p-I-Ph	H	H	CH_2-indol-3-yl	^{n}Bu	H	F	H	OH	H	H
VI-40-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	^{n}Bu	H	F	H	OH	H	H
VI-40-8	p-I-Ph	*	H	*	^{n}Bu	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-41.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-41-1	CH_3	H	H	H	Bz	H	F	H	OH	H	H
VI-41-2	CH_3	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-41-3	CH_3	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-41-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-41-5	CH_3	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-41-6	CH_3	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-41-7	CH_3	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-41-8	CH_3	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-42.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-42-1	Et	H	H	H	Bz	H	F	H	OH	H	H
VI-42-2	Et	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-42-3	Et	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-42-4	Et	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-42-5	Et	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-42-6	Et	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-42-7	Et	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-42-8	Et	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002237

Table VI-43.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-43-1	^{i}Pr	H	H	H	Bz	H	F	H	OH	H	H
VI-43-2	^{i}Pr	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-43-3	^{i}Pr	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-43-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-43-5	^{i}Pr	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-43-6	^{i}Pr	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-43-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-43-8	^{i}Pr	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-44.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-44-1	^{t}Bu	H	H	H	Bz	H	F	H	OH	H	H
VI-44-2	^{t}Bu	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-44-3	^{t}Bu	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-44-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-44-5	^{t}Bu	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-44-6	^{t}Bu	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-44-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-44-8	^{t}Bu	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-45.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-45-1	Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-45-2	Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-45-3	Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-45-4	Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-45-5	Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-45-6	Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-45-7	Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-45-8	Ph	*	H	*	Bz	H	F	H	OH	H	H

Gilead Exhibit 2029
PGR2023-00046 - Page 002238

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-46.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-46-2	p-Me-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-46-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-46-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-46-5	p-Me-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-46-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-46-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-47.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-47-2	p-F-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-47-3	p-F-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-47-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-47-5	p-F-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-47-6	p-F-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-47-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-48.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-48-2	p-Cl-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-48-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-48-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-48-5	p-Cl-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-48-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-48-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H

Gilead Exhibit 2029
PGR2023-00046 - Page 002239

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-49.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-49-2	p-Br-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-49-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-49-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-49-5	p-Br-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-49-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-49-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH	H	H


*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VI-50.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8
VI-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH	H	H
VI-50-2	p-I-Ph	H	H	CH_3	Bz	H	F	H	OH	H	H
VI-50-3	p-I-Ph	H	H	$CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-50-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Bz	H	F	H	OH	H	H
VI-50-5	p-I-Ph	H	H	CH_2Ph	Bz	H	F	H	OH	H	H
VI-50-6	p-I-Ph	H	H	CH_2-indol-3-yl	Bz	H	F	H	OH	H	H
VI-50-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Bz	H	F	H	OH	H	H
VI-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH	H	H

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002240



VII

Table VII-1.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-1-1	CH_3	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-1-2	CH_3	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-1-3	CH_3	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-4	CH_3	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-5	CH_3	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-1-6	CH_3	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-1-7	CH_3	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-1-8	CH_3	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-2.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-2-1	Et	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-2-2	Et	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-2-3	Et	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-4	Et	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-5	Et	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-2-6	Et	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-2-7	Et	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-2-8	Et	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002241

Table VII-3.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-3-1	^{i}Pr	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-3-2	^{i}Pr	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-3-3	^{i}Pr	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-5	^{i}Pr	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-3-6	^{i}Pr	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-3-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-3-8	^{i}Pr	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-4.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-4-1	^{t}Bu	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-4-2	^{t}Bu	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-4-3	^{t}Bu	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-5	^{t}Bu	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-4-6	^{t}Bu	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-4-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-4-8	^{t}Bu	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-5.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-5-1	Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-5-2	Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-5-3	Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-4	Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-5	Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-5-6	Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-5-7	Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-5-8	Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002242

Table VII-6.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-6-1	p-Me-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-6-2	p-Me-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-6-3	p-Me-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-5	p-Me-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-6-6	p-Me-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-6-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-6-8	p-Me-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-7.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-7-1	p-F-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-7-2	p-F-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-7-3	p-F-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-6	p-F-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-7-7	p-F-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-7-8	p-F-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-7-20	p-F-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-8.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-8-1	p-Cl-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-8-2	p-Cl-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-8-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-5	p-Cl-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-8-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-8-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-8-8	p-Cl-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002243

Table VII-9.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-9-1	p-Br-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-9-2	p-Br-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-9-3	p-Br-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-6	p-Br-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-9-7	p-Br-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-9-8	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-9-20	p-Br-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-10.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-10-1	p-I-Ph	H	H	H	CH_3	H	F	H	OH	H	H	NH_2
VII-10-2	p-I-Ph	H	H	CH_3	CH_3	H	F	H	OH	H	H	NH_2
VII-10-3	p-I-Ph	H	H	$CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-5	p-I-Ph	H	H	CH_2Ph	CH_3	H	F	H	OH	H	H	NH_2
VII-10-6	p-I-Ph	H	H	CH_2-indol-3-yl	CH_3	H	F	H	OH	H	H	NH_2
VII-10-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	CH_3	H	F	H	OH	H	H	NH_2
VII-10-8	p-I-Ph	*	H	*	CH_3	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-11.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-11-1	CH_3	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-11-2	CH_3	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-11-3	CH_3	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-11-4	CH_3	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-11-5	CH_3	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-11-6	CH_3	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-11-7	CH_3	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-11-8	CH_3	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002244

Table VII-12.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-12-1	Et	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-12-2	Et	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-12-3	Et	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-12-4	Et	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-12-5	Et	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-12-6	Et	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-12-7	Et	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-12-8	Et	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-13.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-13-1	^{i}Pr	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-13-2	^{i}Pr	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-13-3	^{i}Pr	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-13-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-13-5	^{i}Pr	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-13-6	^{i}Pr	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-13-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-13-8	^{i}Pr	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-14.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-14-1	^{t}Bu	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-14-2	^{t}Bu	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-14-3	^{t}Bu	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-14-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2

Gilead Exhibit 2029
PGR2023-00046 - Page 002245

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-14-5	^{t}Bu	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-14-6	^{t}Bu	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-14-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-14-8	^{t}Bu	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-15.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-15-1	Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-15-2	Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-15-3	Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-15-4	Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-15-5	Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-15-6	Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-15-7	Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-15-8	Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-16.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-16-2	p-Me-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-16-3	p-Me-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-16-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-16-5	p-Me-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-16-6	p-Me-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-16-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002246

Table VII-17.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-17-2	p-F-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-17-3	p-F-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-17-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-17-5	p-F-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-17-6	p-F-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-17-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-18.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-18-2	p-Cl-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-18-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-18-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-18-5	p-Cl-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-18-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-18-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-19.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-19-2	p-Br-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-19-3	p-Br-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-19-4	p-Br-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-19-5	p-Br-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-19-6	p-Br-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-19-7	p-Br-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002247

Table VII-20.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH	H	H	NH_2
VII-20-2	p-I-Ph	H	H	CH_3	Et	H	F	H	OH	H	H	NH_2
VII-20-3	p-I-Ph	H	H	$CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-20-4	p-I-Ph	H	H	$CH_2CH(CH_3)_2$	Et	H	F	H	OH	H	H	NH_2
VII-20-5	p-I-Ph	H	H	CH_2Ph	Et	H	F	H	OH	H	H	NH_2
VII-20-6	p-I-Ph	H	H	CH_2-indol-3-yl	Et	H	F	H	OH	H	H	NH_2
VII-20-7	p-I-Ph	H	H	$CH_2CH_2SCH_3$	Et	H	F	H	OH	H	H	NH_2
VII-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-21.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-21-1	CH_3	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-2	CH_3	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-3	CH_3	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-4	CH_3	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-5	CH_3	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-6	CH_3	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-7	CH_3	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-21-8	CH_3	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-22.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-22-1	Et	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-2	Et	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-3	Et	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-4	Et	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-5	Et	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-6	Et	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-7	Et	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-22-8	Et	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002248

Table VII-23.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-23-1	^{i}Pr	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-2	^{i}Pr	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-3	^{i}Pr	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-4	^{i}Pr	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-5	^{i}Pr	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-6	^{i}Pr	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-7	^{i}Pr	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-23-8	^{i}Pr	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-24.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-24-1	^{t}Bu	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-2	^{t}Bu	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-3	^{t}Bu	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-4	^{t}Bu	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-5	^{t}Bu	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-6	^{t}Bu	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-7	^{t}Bu	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-24-8	^{t}Bu	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-25.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-25-1	Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-2	Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-3	Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-4	Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-5	Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-6	Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-7	Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-25-8	Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002249

Table VII-26.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-26-1	p-Me-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-2	p-Me-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-3	p-Me-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-4	p-Me-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-5	p-Me-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-6	p-Me-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-7	p-Me-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-26-8	p-Me-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-27.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-27-1	p-F-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-2	p-F-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-3	p-F-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-4	p-F-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-5	p-F-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-6	p-F-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-7	p-F-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-27-8	p-F-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Table VII-28.

№	R^1	R^2	R^{3a}	R^{3b}	R^4	R^5	R^6	X	Y	R^7	R^8	R^9
VII-28-1	p-Cl-Ph	H	H	H	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-2	p-Cl-Ph	H	H	CH_3	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-3	p-Cl-Ph	H	H	$CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-4	p-Cl-Ph	H	H	$CH_2CH(CH_3)_2$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-5	p-Cl-Ph	H	H	CH_2Ph	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-6	p-Cl-Ph	H	H	CH_2-indol-3-yl	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-7	p-Cl-Ph	H	H	$CH_2CH_2SCH_3$	^{i}Pr	H	F	H	OH	H	H	NH_2
VII-28-8	p-Cl-Ph	*	H	*	^{i}Pr	H	F	H	OH	H	H	NH_2

*R^2 and R^{3b} joined together by $(CH_2)_3$ to form five-membered ring.

Gilead Exhibit 2029
PGR2023-00046 - Page 002250